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1 Homo_sapiens_PACT 201 LL TW SLRNS GEKI L L........................IS TNVVGHSLGC H P NL KRSL ...SIPNTDYIQL S
Bos_taurus_PACT 201 LL TW SLRNS GEKI L L........................IS TNMVGHSLGC H P NL KRSL ...SIPNTDYIQL S
Mus_musculus_PACT 201 LL TW SLRNS GEKI L L........................IS TNVVGHSLGC H P NL KRSL ...SLPNTDYIQL S
Rattus_norvegicus_PACT 201 LL TW SLRNS GEKI L L........................IS TNVVGHSLGC H P NL KRSL ...SLPNTDYIQL S
Felis_catus_PACT 176 LL TW SLRNS GEKI L L........................IS TNVVGHSLGC H P NL KRSL ...SIPNTDYIQL S
Anolis_carolinensis_PACT 392 LL TW LRNS EKI L L........................IS N..LSRNLGC DT SR TL KMSP ...SIPNTDYVHL R
Xenopus_laevis_PACT 197 LL TW S RNS GEKI L L........................IP NKLIGNKMGC D M S SM KRSP ...SIPNTDYVKM K
Danio_rerio_PACT 180 LSLRNS GEK L L...........................EITWSPPSRVYVE T VSL KRTP ...SLPNTDYIQM L
2 Homo_sapiens_TRBP 247 LL TW SLRNS GEKI L L.IGVG...................SR DGLRNRGPGC D V LS RSCS GSLGALGPACCRV S
Bos_taurus_TRBP 247 LL TW SLRNS GEKI L L.IGVG...................SR DGLRNRGPGC D V LS RSCS GSLGALGPACCSV S
Felis_catus_TRBP 247 LL TW SLRNS GEKI L L.IGVG...................SR DGLRNRGPGC D V LS RSCS GALGALGPACCSV S
Mus_musculus_TRBP 246 LL TW SLRNS GEKI L.IGVS...................SR DGLRNRGPGC D V LS RSCSVGSLGALGSACCSV S
Rattus_norvegicus_TRBP 246 LL TW SLRNS GEKI L.IGVS...................SR DGLRNRGPGC D V LS RNCSVGSLGSLGSACCSI S
Xenopus_laevis_TRBP 238 LL TW SLRNS GEKI L L.V......................GK DGSRSRGTAC D S LH RSNP ...TILSSGFCSL Q
Anolis_carolinensis_TRBP 245 LTW SLRNS GEKI L L.ITAG...................NKMDGVKGRGSGC D A LH KSNP ...GVLNAGFCSL E
Danio_rerio_TRBP 227 LL TW SLRNS GEKI L L.MQIG...................GR EGGKSKGLGC D A LQ RCHP GQSDSIDSNFCSL R
3 Branchiostomata_floridae_PACT/TRBP 207 LTW LRNS GEKI L L........................TGVKPMHAARIGI AT A TR KSTS ...STPNSNYCQL Q
Crassostrea_gigas_PACT/TRBP 197 LN LLNAS....EIRASYTALKEGKVKLPIPSPQQNKEIQQFYQKIK N.....HKIKNSK ...TAPATNYCQM Q
4 Drosophila_melanogaster_Loqs 340 LL L N G K L LSSE........NYYGELKDI..SVPT TTQHSNKVSQFHKT K AT K LLK QKTC ...KNNKIDYIKL G
Danaus_plexippus_Loqs 277 LL L S G L LAR...........YADLKDS..KITT TTSHSHKVSQFHKH KQ V PNLVK QVTP ...NNKDFNFVQF Q
Apis_mellifera_Loqs 259 LL SL S G K L LAR...........YADLK..GSKIST TTIHSLKVSQFHK KS T V LFE QNTC N...DGDVNLVQF Q
Daphnia_pulex_Loqs 167 LL.....LED...........................................EDEEVA ...KDPCLDYFQL R
1 Homo_sapiens_PACT 247 F Y DI E QCL P V G A AA AL YE EQ L S G ELST T CH S N Q LKIIAK G NIT D L AN QY A S I GISCGN QSD H IAERK
Bos_taurus_PACT 247 F Y DI E QCL P V G A AA AL YE EQ L E S G ELST T CH S N Q LKIIAK G NIT L AN QY A S I GISCSS QSD H IAERK
Mus_musculus_PACT 247 F Y DI E QCL P V G A AA AL YE EQ L E S G ELST T CH S N Q LKIIAS G NIT L AN QY A S I GISCGN QSD H IAERK
Rattus_norvegicus_PACT 247 F Y DI E QCL P V G A AA AL YE EQ L E S G ELST T CH S N Q LKIIAK G SIT L AN QY A S I GISCGN QSD H IAERK
Felis_catus_PACT 222 F Y DI E QCL P V G A AA AL YE EQ L E S G ELST T CH S N Q LKIIAK G NIT L AN QY A S I GISCGN QSD H IAERK
Anolis_carolinensis_PACT 436 F Y DI E QCL P V G A AA AL YE EQ L E S G ELST T CH N Q LKIMIAQ G HAT L VN QF A H I TGISWGN HND H AGRK
Xenopus_laevis_PACT 243 F Y DI E QCL P V G A AA AL YE L S G ELST T CH N Q LKIMDVAE LD NLT D L VN QY A N I TGISCGN HND H CIKK
Danio_rerio_PACT 223 F Y DI E QCL P V G A AA AL YE E G ELST T CH S N Q KISL LG QVT I D LTVN QY V R V GVTSSN HNA H I MVASKH
2 Homo_sapiens_TRBP 300 F Y DI E QCL P V G A AA AL YE EQ L E S G ELST T CH S Q LKIMLSE A HVS L LS LC V Q A ATTREA RGE RR AGSK
Bos_taurus_TRBP 300 F Y DI E QCL P V G A AA AL YE EQ L E S G ELST T CH S Q LKIMLSE A HVS L LS LC V Q A AATREA RGE RR AGSK
Felis_catus_TRBP 300 F Y DI E QCL P V G A AA AL YE EQ L E S G ELST T CH S Q LKIMLSE A HVS L LS LC V Q A AATREA RGE CR AGSK
Mus_musculus_TRBP 299 F Y DI E QCL P V G A AA AL YE EQ L E S G ELST T C S Q L IMLSE A HVS L LS LC V Q A Y ATTREA RGD HR R AGSK
Rattus_norvegicus_TRBP 299 F Y DI E QCL P V G A AA AL YE EQ L E S G ELST T C S Q L IMLSA A HVS L LS LC V Q A Y ATTREA RGD RR R AGSK
Xenopus_laevis_TRBP 285 F Y DI E QCL P V G A AA AL YEQ L S G ELST T CH S N Q LKIMDLSE S QIS D R LS LC V Q T ATTRDA RAN H AGGK
Anolis_carolinensis_TRBP 295 F Y DI E QCL P V G A AA AL YE EQ L S G ELST T CH S N Q LKIMLSE S DIS D M LS LY V Q T ATSRHA RVD R AGGK
Danio_rerio_TRBP 280 F Y DI E QCL P V G A AA AL YE EQ L E S G ELST T CH N Q LKIMLSE R GVS R LS LY V Q I FASSLDA RAS H AGGK
3 Branchiostomata_floridae_PACT/TRBP 253 F Y DI E QCL P V G A AA AL YE EQ L E S L T T CH N Q LK MLAE N EVE L ASSLH VQ T Q V QGHTRDE HAH H L VRRA
Crassostrea_gigas_PACT/TRBP 258 F Y DI E QCL P V G A AA AL YE Q S G LST CH N Q LK MISEV R EVS M A I TK QR VQ L VA TGQTVDE HAH H L TKT.
4 Drosophila_melanogaster_Loqs 400 F Y DI E QCL P V G A AA AL YE E E G LST CH S N LKIMIAT NQ EVT V KTFS QF VQ L VG GPTAAD QRH Q E TKK.
Danaus_plexippus_Loqs 334 F Y DI E QCL P V G A AA AL YE EQ E G LST C S N LKIMIAS S EVT V KTMT RS VQ L VA Y GLTSKD QSS Q E TKK.
Apis_mellifera_Loqs 316 F Y DI E QCL P V G A AA AL YE EQ E S G LST C N LKIMIAS Q EVT V K IS KC VQ L VA Y CGVTSKD QAS Q E TKK.
















































































2.1.4 Culture	and	overexpression	10	mL	Luria	Broth	(LB)/kanamycin	was	inoculated	with	a	single	colony,	and	grown	for	6	hours	at	37	˚C	with	shaking	at	120-180	rpm	(media	and	buffer	recipes	are	given	in	section	4	below).	The	optical	density	at	600	nm	(OD600)	was	measured,	then	a	volume	Vin	was	centrifuged	and	resuspended	in	50	mL	M9/kanamycin	minimal	media,	such	that	the	new	OD600	was	0.05.	!"# = (&'())*+	-./01231./)∙(+"#62	7*218/)(9/:"./9	+"#62	&'())) = &'())∙;<	82<.<; 		This	M9	preculture	was	grown	for	16	hours	at	37	˚C.	Then	the	OD600	was	measured,	and	a	volume	resuspended	in	1	L	M9/kanamycin	to	give	a	starting	OD600	of	0.05.		This	culture	was	grown	at	37	˚C	until	it	reached	an	OD600	of	0.6-0.8,	at	which	point	it	was	supplemented	with	IPTG	to	a	final	concentration	of	1	mM.	It	was	then	grown	for	14-16	hours	at	20	˚C,	and	then	centrifuged	for	20	mins	at	5000	RCF		to	pellet	the	cells.	The	cell	pellet	was	then	lysed	immediately	(as	described	below),	or	stored	at	-20	˚C	until	ready	for	use.	
2.2 Protein	purification	
2.2.1 Assessing	solubility	of	constructs	To	determine	whether	the	constructs	were	expressed	and	soluble,	cultures	were	grown	as	above,	but	were	induced	and	harvested	after	the	50	mL	M9	culture.	Cell	pellets	were	resuspended	in	a	volume	of	lysis	buffer	supplemented	with	1	mg/mL	hen	egg	lysozyme	(Sigma)	and	0.5%	(v/v)	Triton	X-100,	to	give	a	final	OD600	of	40.	







PACT-D3	 8.1	 6000	PACT-Ext-D3	 11.6	 11600	TRBP-D3	 8.5	 3100	TRBP-Ext-D3	 11.9	 8650	Loqs-D3	 8.1	 4500		 	 		 	 		 	 		
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To	remove	the	solubility	tag	from	the	eluted	protein,	His-tagged	HRV	3C	protease	(produced	by	the	University	of	York	Technology	Facility)	was	added	in	a	ratio	of	1	mg	protease	per	50	mg	eluted	protein.	This	mixture	was	dialysed	at	4	˚C	for	14	hours	against	a	>50-fold	larger	volume	of	20	mM	Tris,	0.5	M	NaCl,	0.5	mM	dithiothreitol	(DTT),	pH	7.5,	using	a	dialysis	membrane	with	a	molecular	weight	cut-off	(MWCO)	of	3.5	kDa	(Spectrum	Labs).	DTT	was	necessary	for	efficient	cleavage,	possibly	by	preventing	oxidation	of	a	catalytic	cysteine	residue	(Matthews	et	al.,	1994).	A	second	nickel	affinity	purification	was	then	carried	out	to	separate	the	cleaved	protein	of	interest	(found	in	the	column	flow	through)	from	the	His-solubility	tag	and	3C	protease.	To	remove	remaining	impurities	(mostly	MBP	and	uncleaved	protein),	the	protein	was	first	concentrated	using	spin	columns	with	a	5	kDa	MWCO	(VivaSpin)	to	a	volume	of	approximately	500	µL.	This	was	then	passed	over	a	S75	Superdex	16/60	column	(GE	Healthcare)	equilibrated	in	size	exclusion	buffer	(see	Chapter	6,	section	6.3),	at	a	flow	rate	of	1	mL/min.	Fractions	were	visualised	by	SDS-PAGE,	and	fractions	containing	the	protein	of	interest	were	pooled	and	concentrated.	For	samples	requiring	TCEP,	an	additional	dialysis	step	against	50	mL	of	the	TCEP-containing	buffer	was	performed.	





Component	 Concentration	(g/L)	Tryptone	 10	Yeast	Extract	 5	NaCl	 10	Agar	(only	if	making	plates)	 15	Autoclave.	Optionally	add	50	µg/mL	kanamycin	before	use.		
M9	base	
Component	 Concentration	(g/L)	Na2HPO4	(anhydrous)	 6	KH2PO4	(anhydrous)	 3	NaCl	 0.5	NH4Cl	*	 1	Adjust	pH	to	6.8-7.2,	then	autoclave.	*	For	50	mL	cultures,	14NH4Cl	was	used.	For	1	L	cultures,	15NH4Cl	was	used	(Cambridge	Isotope	Laboratories,	Inc.)		
1	L	M9	
Component	 Volume	M9	base	 1	L	20%	D-Glucose	*	 10	mL	1	M	MgSO4	 1	mL	100	mM	CaCl2	 1	mL	100	mM	MnCl2	 1	mL	
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50	mM	ZnSO4	 1	mL	100	mM	FeCl3	 0.5	mL	500x	Vitamin	Cocktail	 2	mL	50	mg/mL	Kanamycin	 1	mL	Nb.	All	components	except	the	M9	base	are	passed	through	a	0.22	µm	filter	before	use.	*	When	producing	samples	for	3D	NMR	experiments,	99%	[U-13C]-labelled	D-glucose	was	used	(Cambridge	Isotope	Laboratories,	Ltd.)		
50	mL	M9	500x	vitamin	cocktail	




Component	 Concentration	Tris	 20	mM	NaCl	 150	mM	CaCl	 10	mM	MgCl	 10	mM	DNase	I	 20	µg/µL	RNase	A	 20	µg/µL	Leupeptin	 1	µg/µL		
Nickel	affinity	purification	buffers	
Component	 Ni-IMAC	binding	buffer	 Ni-IMAC	elution	buffer	Tris	 20	mM	 20	mM	NaCl	 0.5	M	 0.5	M	Imidazole	 20	mM	 0.5	M	Adjust	pH	to	7.5,	then	pass	through	0.22	µm	filter		
SEC-MALLS	buffer	





Component	 15%	resolving	gel	(10	mL)	 4%	Stacking	gel	(5mL)	30%	Acrylamide	 4.9	mL	 650	µL	1.5	M	Tris,	pH8.8	 2.5	mL	 -	0.5	M	Tris	pH	6.8		 -	 1.25	mL	10%	SDS	 100	µL	 50	µL	Distilled	H2O	 2.5	mL	 3.05	mL	10%	APS*	 100	µL	 50	µL	TEMED*	 10	µL	 5µL	*	Add	just	before	pouring		
SDS-PAGE	Running	buffer	
Component	 Concentration	Tris	 3	g/L	Glycine	 14	g/L	SDS	 1	g/L		
SDS-PAGE	sample	buffer	
Component	 	1	M	Tris	pH	7.2	 1	mL	Distilled	H2O	 3	mL	10%	SDS	 10	mL	Bromophenol	blue	 0.06	g	Glycerol	 12	g			
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1	L	Coomassie	stain	
Component	 	Ethanol	 450	mL	Acetic	acid	 100	mL	Distilled	H2O	 450	mL	Brilliant	Blue	R	 2.5	g		
1	L	Destain	






3.1.1 Theoretical	basis	for	molecular	weight	measurement	using	MALLS	MALLS	exploits	the	fact	that	both	the	degree	of	light	scattering	and	the	refractive	index	of	a	polymer	solution	vary	with	concentration	and	molecular	weight,	but	with	different	dependencies.	The	refractive	index	depends	only	on	the	mass	concentration	of	the	polymer,	and	is	given	by	the	equation	D E = D:*27/#3 + 9#90 E		 	 	 	 	 	 	 	 [3.1]	where	n	is	the	refractive	index,	c	is	the	protein	mass	concentration,	and	dn/dc	is	the	difference	in	refractive	index	per	concentration	unit	of	protein.		For	proteins,	 9#90 	lies	in	a	fairly	narrow	range	between	0.18	and	0.20	mL	g-1,	and	is	generally	not	measured	directly	(Zhao,	Brown	and	Schuck,	2011).	 9#90 	does	also	depend	on	the	refractive	index	of	the	solvent,	but	this	is	usually	neglected,	despite	the	strong	dependence	of	n	on	salt	concentration	(Tan	and	Huang,	2015).	The	light	scattered	by	a	sample	of	(possibly	oligomeric)	protein	is	proportional	to	both	the	mass	concentration	and	the	molecular	weight.	I	will	first	give	a	physical	explanation,	then	briefly	describe	a	more	mathematical	derivation.		
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Consider	two	solutions	of	a	particular	protein	with	the	same	concentration,	but	different	oligomeric	states:	one	is	dimeric,	while	the	other	is	monomeric	(perhaps	because	it	has	a	mutation	on	its	dimerisation	interface).	As	a	light	wave	passes	through	the	solution	of	monomers,	it	will	induce	charge	polarisation	in	each	protein	molecule,	causing	it	to	act	as	a	driven	oscillating	dipole.		In	the	monomeric	protein	solution,	each	dipole	will	give	rise	to	a	wave	with	amplitude	GH 9#90 ,	where	M	is	the	protein	molecular	weight,	and	a	is	a	constant.	The	waves	from	each	dipole	add	together,	but	because	the	proteins	are	randomly	distributed	through	space,	the	waves	are	not	in	phase	with	one	another	and	the	overall	amplitude	is	proportional	to	 EGH 9#90 .	The	intensity	is	the	square	of	the	amplitude,	so	the	overall	intensity	of	scattered	light	is	proportional	to	EGIHI 9#90 I	In	the	dimeric	sample,	each	protomer	will	again	generate	a	wave	with	amplitude	GH 9#90 .	But	this	time,	the	waves	from	the	two	halves	of	each	dimer	will	interfere	constructively,	so	each	dimer	gives	rise	to	a	wave	of	amplitude	2GH 9#90 .	The	molar	concentration	of	dimer	is	half	the	monomer	concentration,	so	these	sum	to	a	total	amplitude	of	 0I 2GH 9#90 ,	giving	a	final	intensity	of	2EGIHI 9#90 I.	So,	the	dimeric	solution	scatters	twice	as	much	light	as	the	monomeric	solution,	despite	having	the	same	protein	concentration.			A	full	mathematical	treatment	of	light	scattering	from	a	polymer	is	given	by	Zimm	(Zimm,	1948),	and	summarised	by	Wyatt	(Wyatt,	1993).	Briefly,	we	start	by	assuming	a	polymer	is	made	up	of	n	identical	scattering	segments,	which	are	distributed	relative	to	one	another	according	to	a	function	K(L).	This	distribution	function	accounts	both	for	the	probability	of	finding	a	segment	within	the	same	polymer	chain	at	a	distance	r,	and	the	probability	of	finding	a	segment	from	a	different	polymer	chain.	The	scattering	from	a	solution	with	N	polymer	molecules	in	a	volume	V	is	then	given	by	the	Raleigh-Gans-Debye	approximation:	M N = O∗#QRQSQ K L exp IW"X∙YZ [L	 	 	 	 	 	 	 [3.2]	where	M(N)	is	the	excess	Raleigh	scattering	at	an	angle	theta	between	the	incident	and	scattered	rays,	K*	is	a	constant	determined	by	the	refractive	indexes	of	the	
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(seAUC)	Sedimentation	equilibrium	analytical	ultracentrifugation	is	a	method	of	determining	molecular	weight	and	equilibrium	association	properties	of	proteins	based	on	their	sedimentation	properties.	During	centrifugation,	molecules	experience	a	force		{ = H 1 − 7| }IL	 	 	 	 	 	 	 	 	 [3.7]	where	M	is	the	protein	molar	mass,	~	is	the	partial	specific	volume	of	the	protein,	K	is	the	solvent	density,	}	is	the	angular	speed	and	r	is	the	radial	distance	from	the	rotor	axis.	This	force	causes	them	to	move	towards	the	outer	edge	of	the	rotor	until	the	centrifugal	force	is	balanced	by	diffusion,	forming	a	concentration	gradient.	The	analytical	ultracentrifuge	is	equipped	with	a	spectrophotometer	that	allows	the	absorbance	to	be	measured	at	different	radii,	allowing	the	radial	distribution	of	protein	to	be	calculated.	This	data	can	then	be	used	to	calculate	molecular	weight	and	association	constants,	and	additionally	detect	the	presence	of	aggregates	or	non-ideality.	When	a	protein	sample	is	centrifuged,	it	distributes	itself	in	accordance	with	the	Boltzmann	distribution,	with	higher	concentrations	in	regions	with	lower	(more	
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negative)	potential	energy	(Brautigam,	2011).	It	can	be	shown	that	the	equilibrium	distribution	of	protein	is	given	by:	
Ä 0 ..Q = 	H 1 − 7| ÅQ	IÇÉ	 	 	 	 	 	 	 	 [3.8]	where	c(r)	is	the	mass	concentration	at	r,	R	is	the	gas	constant	and	T	the	temperature.	Of	the	variable	parameters,	}	and	T	are	controlled	by	the	experimenter,	while	~	and	K	can	be	estimated	accurately	with	knowledge	of	the	protein	sequence	and	buffer	composition	respectively.	This	allows	the	molar	mass	to	be	calculated	for	a	single	species	in	solution	simply	by	plotting	ln(c(r))	against	r2.	For	solutions	containing	a	mixture	of	oligomeric	states,	or	with	a	mixture	of	different	proteins,	more	complicated	data	analysis	is	required.	For	analysing	a	mixture	of	monomer	and	dimer,	the	full	equation	for	the	radial	concentration	distribution	is	given	by:	






































4.2.1 Physical	basis	of	the	NMR	signal	All	nuclei	have	a	quantum-mechanical	property	called	spin,	which	is	determined	by	the	arrangement	of	protons	and	neutrons	within	the	nucleus.	Nuclei	of	a	given	isotope	have	either	zero	(12C,	16O),	½	(1H,	15N,	13C,	19F),	or	higher	order	spin	quantum	numbers.	Nuclei	with	spin	½	act	as	magnetic	dipoles,	so	can	interact	with	electromagnetic	fields.	In	particular,	a	nuclear	dipole	oriented	perpendicular	to	an	external	magnetic	field	will	precess	at	its	Larmor	frequency:		} = −ìç	where	ì	is	the	gyromagnetic	ratio	for	that	nucleus,	and	ç	is	the	magnetic	field	strength.		In	the	absence	of	an	external	magnetic	field,	the	energy	of	each	nuclear	dipole	is	independent	of	its	orientation.	Therefore,	the	dipoles	in	a	sample	will	be	distributed	isotropically,	leading	to	zero	net	magnetisation.	When	an	external	field	is	applied,	the	energy	becomes	dependent	on	the	angle	between	the	dipole	and	the	field:	spins	oriented	parallel	to	the	magnetic	field	have	a	lower	energy	than	those	oriented	antiparallel,	resulting	in	a	net	magnetisation	parallel	to	the	field	at	thermal	equilibrium.	In	the	simplest	form	of	Fourier-transform	NMR	spectroscopy,	a	radio-frequency	(r.f.)	pulse	at	the	Larmor	frequency	causes	all	spins	to	rotate	by	90°,	leading	also	to	a	rotation	of	net	magnetisation	into	a	plane	perpendicular	to	the	external	field.	As	the	spins	precess,	the	net	magnetisation	precesses	with	them,	and	can	be	
	 71	
detected	by	a	receiver	coil	within	the	probe.	Other	experiments	utilise	a	more	complex	initial	series	of	pulses	and	delays,	but	detect	the	final	signal	in	the	same	way.	Over	time,	the	precessing	spins	lose	coherence	(transverse	relaxation)	and	return	to	thermal	equilibrium	(longitudinal	relaxation).	These	processes	are	discussed	further	in	the	sections	below.	


















































































































imaginary)	cbcanhgpwg3d	 1H	 4.68	 14	 2048	
15N	 118	 28	 64	
13C	 39	 75	 128	cbcaconhgpwg3d	 1H	 4.68	 14	 2048	
15N	 118	 28	 64	
13C	 39	 75	 128	hncogpwg3d	 1H	 4.68	 14	 2048	
15N	 118	 28	 64	









+	imaginary)	hncacbgpwg3d,	cbcaconhgpwg3d	 1H	 4.7	 14	 2048	15N	 118	 28	 80	
13C	 39	 75	 200	b_hncogp3d	 1H	 4.70	 14	 2048	
15N	 118	 28	 56	
13C	 176	 16	 32	hccconhgpwg3d2	 1H	 4.69	 14	 2048	
15N	 118	 28	 56	
1H	 4.69	 14	 128	ccconhgp3d	 1H	 4.69	 14	 2048	
15N	 118	 28	 56	
13C	 40	 70	 128	hsqcctetgpsp	 1H	 4.73	 14	 2048	
13C	 39	 70	 400	hcchdigp3d	 1H	 4.75	 14	 2048	
13C	 39	 70	 256	











imaginary)	noesyhsqcf3gpwg3d	 1H	 4.73	 14	 2048	
15N	 118	 32	 128	
1H	 4.73	 14	 512	noesyhsqcetgp3d	 1H	 4.69	 14	 2048	
13C	 39	 39	 128	
1H	 4.69	 14	 460	
13C-filtered	NOESY-HSQC	 1H	 4.7	 16	 2048	13C	 39	 39	 52	








squares	fitting,	using	a	Gauss-Newton	algorithm.	The	equations	describing	the	exchange	model	are	given	below	(Farrow,	Zhang,	et	al.,	1994;	3rd,	Kroenke	and	Loria,	2001):	M¢¢ £ = M<§¢ ZQáÇ•áñj¶ /ß®i©k¶ê Z®áÇ•áñj¶ /ßQi©k¶ZQáZ® 	 	 	 	 	 [4.2]	M™™ £ = M<§™ ZQáÇ´áñj¶ /ß®i©k¶ê Z®áÇ´áñj¶ /ßQi©k¶ZQáZ® 		 	 	 	 [4.3]	M¢™ £ = M<§¢†/° /äß®i©k¶á/äßQi©k¶ZQáZ® 	 	 	 	 	 	 	 [4.4]	M¢™ £ = M<§™†/° /äß®i©k¶á/äßQi©k¶ZQáZ® 	 	 	 	 	 	 	 [4.5]	M¢ £ = ¨®¨) M¢¢ + M™¢ 		 	 	 	 	 	 	 	 [4.6]	M™ £ = ¨®¨) M™™ + M¢™ 		 	 	 	 	 	 	 	 [4.7]	\Ü = ÜI ≠¢ + ≠™ + 2†/° + ≠¢ − ≠™ I + 4†/°I 	 	 	 	 	 [4.8]	\Ü = ÜI ≠¢ + ≠™ + 2†/° − ≠¢ − ≠™ I + 4†/°I 	 	 	 	 	 [4.9]	Where:		 IAA	and	IBB	are	the	heights	of	the	auto	peaks	for	states	A	and	B	in	the	EXSY	spectra;		 IAB	and	IBA	are	the	heights	of	the	exchange	peaks	in	the	EXSY	spectra;		 IA	and	IB	are	the	peak	heights	for	states	A	and	B	in	the	T1	relaxation	spectra;		 I0	and	I1	are	scaling	factors	for	the	EXSY	and	T1	relaxation	spectra	respectively;		 CA	and	CB	are	account	for	initial	differences	in	intensity	of	states	A	and	B;		 RA	and	RB	are	the	longitudinal	relaxation	rates	of	states	A	and	B;		 kex	is	the	exchange	rate	between	states	A	and	B;		 tmix	is	the	mixing	time	allowed	for	relaxation	and	exchange.	Note	that	the	model	as	given	above	assumes	that	the	rate	of	conversion	from	A	to	B	and	from	B	to	A	are	equal,	and	only	accounts	for	relaxation	that	occurs	during	the	mixing	time,	not	during	other	parts	of	the	pulse	sequence.	This	would	be	expected	to	give	equal	populations	to	each,	but	in	practice	deviations	occur,	
	 86	












Name	 Sequence	 Tm/˚C	PACT	forward	 aatgaattcgaacATGTCCCAGAGCAGGCACC	 64.8	PACT-D3	forward	 aatgaattcgaacACAGATTACATCCAGCTGC	TTAGTGAAATTG	 63.1	PACT-Ext-D3	forward	 aatgaattcgaacGGACATTCTTTAGGATGTA	CTTGGCATTCCTTG	 64.6	PACT	reverse	 acaacttctagaTTACTTTCTTTCTGCTATTA	TCTTTAAATACTGCAAAGCA	 62.1		
5.3.2 Construction	of	c-myc	tag	expression	vectors	Oligonucleotides	encoding	c-myc	and	flanking	sticky-ended	NotI	and	BSP199I	restriction	sites	(see	table	two)	were	annealed	by	heating	to	95˚C	for	5	minutes,	followed	by	a	slow	cooling	to	room	temperature.	pSF-CMV-PURO-NH2-FLAG	vector	(OG3213,	Oxford	Genetics)	was	then	cleaved	using	NotI	and	Bsp199I,	and	purified	using	a	Wizard	SV	Gel	and	PCR	Cleanup	Kit	(Promega).	The	annealed	oligos	and	linearized	vector	were	then	ligated	using	T4	DNA	ligase,	and	verified	by	sequencing.	
Table	5.2.	Oligonucleotides	used	in	construction	of	c-myc	expression	vector	











Antibody	 Description	 Dilution	 Manufacturer,	
catalogue	number	
a-hsPACT	 Rabbit	polyclonal	 1:1000*	 Abcam,	ab31967	
a-c-myc	 Mouse	monoclonal	(9E10)	IgG1		 1:500*	 Sigma-Aldrich,	M4439	
a-FLAG	 Mouse	monoclonal	(M2)	IgG1	 1:5000*	 Sigma-Aldrich,	F3165	
a-beta	Actin	 Mouse	monoclonal	(AC-15)	IgG1	 1:50000*	 Abcam,	ab6276	
a-rabbit	IgG	 Goat	polyclonal	coupled	to	HRP	 1:5000**	 Dakocytomation,	P0448	




























































A  PACT-D3 B  PACT-Ext-D3
C  TRBP-D3
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induced chemical shift 
change (ppm/kbar)
Difference in pressure-
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PACT-Ext-D3 208 L N G K L L L E E F Y DI EGCTW S R S E I DYI L S IA Q NIT L D LSSL H P NL KR...SL SIPNT Q K G A
TRBP-Ext-D3 L N G K L L L E E F Y DI EGCTW S R S E IL S Q V L E LSGP D V S RSCSLGS GALGPACCRV LSE A H S L
Loqs-Ext-D3 L N G K L L L E E F Y DI EL DYI L IA N EVT EKVSQFHKT K AT K L K QK...TC KNNKI K G T Q V KTF
consensus>50 ..gctw.sLrNs.GeKil.L.......L.....dyi.lLsEia.E#.Fn!tYlDI#Els.
TLoqs-D3
PACT-Ext-D3 G QCL LST P VCHGS A AA AL YLKIQY E IT G N Q D N Q A KN A S ISCG S H I ER
TRBP-Ext-D3 G QCL LST P VCHGS A AA AL YLKIS VE T T E Q MA KLC Q A AT REA RG RR GS


































































































































































































































60 ng DNA per well 120 ng DNA per well



























































































































































































































































































































































































ATGGGCAGCA GCCATCATCA TCATCATCAC AGCAGCATGA AAATCGAAGA 
AGGTAAACTG GTAATCTGGA TTAACGGCGA TAAAGGCTAT AACGGTCTCG 
CTGAAGTCGG TAAGAAATTC GAGAAAGATA CCGGAATTAA AGTCACCGTT 
GAGCATCCGG ATAAACTGGA AGAGAAATTC CCACAGGTTG CGGCAACTGG 
CGATGGCCCT GACATTATCT TCTGGGCACA CGACCGCTTT GGTGGCTACG 
CTCAATCTGG CCTGTTGGCT GAAATCACCC CGGACAAAGC GTTCCAGGAC 
AAGCTGTATC CGTTTACCTG GGATGCCGTA CGTTACAACG GCAAGCTGAT 
TGCTTACCCG ATCGCTGTTG AAGCGTTATC GCTGATTTAT AACAAAGATC 
TGCTGCCGAA CCCGCCAAAA ACCTGGGAAG AGATCCCGGC GCTGGATAAA 
GAACTGAAAG CGAAAGGTAA GAGCGCGCTG ATGTTCAACC TGCAAGAACC 
GTACTTCACC TGGCCGCTGA TTGCTGCTGA CGGGGGTTAT GCGTTCAAGT 
ATGAAAACGG CAAGTACGAC ATTAAAGACG TGGGCGTGGA TAACGCTGGC 
GCGAAAGCGG GTCTGACCTT CCTGGTTGAC CTGATTAAAA ACAAACACAT 
GAATGCAGAC ACCGATTACT CCATCGCAGA AGCTGCCTTT AATAAAGGCG 
AAACAGCGAT GACCATCAAC GGCCCGTGGG CATGGTCCAA CATCGACACC 
AGCAAAGTGA ATTATGGTGT AACGGTACTG CCGACCTTCA AGGGTCAACC 
ATCCAAACCG TTCGTTGGCG TGCTGAGCGC AGGTATTAAC GCCGCCAGTC 
CGAACAAAGA GCTGGCGAAA GAGTTCCTCG AAAACTATCT GCTGACTGAT 
GAAGGTCTGG AAGCGGTTAA TAAAGACAAA CCGCTGGGTG CCGTAGCGCT 
GAAGTCTTAC GAGGAAGAGT TGGCGAAAGA TCCACGTATT GCCGCCACCA 
TGGAAAACGC CCAGAAAGGT GAAATCATGC CGAACATCCC GCAGATGTCC 
GCTTTCTGGT ATGCCGTGCG TACTGCGGTG ATCAACGCCG CCAGCGGTCG 
TCAGACTGTC GATGAAGCCC TGAAAGACGC GCAGACTCGT ATCACCAAGG 
GCCTGGAAGT TCTGTTCCAG GGACCAGCAA TG 
 
MGSSHHHHHH SSMKIEEGKL VIWINGDKGY NGLAEVGKKF EKDTGIKVTV 
EHPDKLEEKF PQVAATGDGP DIIFWAHDRF GGYAQSGLLA EITPDKAFQD 
KLYPFTWDAV RYNGKLIAYP IAVEALSLIY NKDLLPNPPK TWEEIPALDK 
ELKAKGKSAL MFNLQEPYFT WPLIAADGGY AFKYENGKYD IKDVGVDNAG 
AKAGLTFLVD LIKNKHMNAD TDYSIAEAAF NKGETAMTIN GPWAWSNIDT 
SKVNYGVTVL PTFKGQPSKP FVGVLSAGIN AASPNKELAK EFLENYLLTD 
EGLEAVNKDK PLGAVALKSY EEELAKDPRI AATMENAQKG EIMPNIPQMS 
AFWYAVRTAV INAASGRQTV DEALKDAQTR ITKGLEVLFQ^GPAM 
 The	cleavage	site	is	marked	by	^.		
PACT-D3	(239-313):	
ACCGATTATA TTCAGCTGCT GTCTGAAATT GCGAAAGAAC AGGGCTTTAA 
CATCACCTAT CTGGATATTG ATGAACTGAG CGCGAACGGC CAGTATCAGT 
	 185	
GCCTGGCCGA ACTGAGCACC AGCCCGATTA CCGTGTGCCA TGGCAGCGGC 
ATTAGCTGCG GCAACGCGCA GTCTGATGCG GCGCATAACG CGCTGCAGTA 
TCTGAAAATT ATCGCGGAAC GCAAA 
 
TDYIQLLSEI AKEQGFNITY LDIDELSANG QYQCLAELST SPITVCHGSG 
ISCGNAQSDA AHNALQYLKI IAERK 	
PACT-Ext-D3	(208-313):	
GGCCATAGCC TGGGCTGCAC CTGGCATAGC CTGCGTAACA GCCCGGGTGA 
AAAAATTAAC CTGCTGAAAC GTAGCCTGCT GTCTATTCCG AACACCGATT 
ATATTCAGCT GCTGTCTGAA ATTGCGAAAG AACAGGGCTT TAACATCACC 
TATCTGGATA TTGATGAACT GAGCGCGAAC GGCCAGTATC AGTGCCTGGC 
CGAACTGAGC ACCAGCCCGA TTACCGTGTG CCATGGCAGC GGCATTAGCT 
GCGGCAACGC GCAGTCTGAT GCGGCGCATA ACGCGCTGCA GTATCTGAAA 
ATTATCGCGG AACGCAAA 
 
GHSLGCTWHS LRNSPGEKIN LLKRSLLSIP NTDYIQLLSE IAKEQGFNIT 
YLDIDELSAN GQYQCLAELS TSPITVCHGS GISCGNAQSD AAHNALQYLK 
IIAERK 	
TRBP-D3	(293-366):	
GCGTGTTGCC GTGTTCTGTC TGAACTGAGC GAAGAACAGG CGTTTCATGT 
GAGCTATCTG GATATTGAAG AACTGAGCCT GAGCGGCCTG TGCCAGTGCC 
TGGTGGAACT GAGCACCCAG CCGGCGACCG TGTGTCATGG TAGCGCGACC 
ACCCGTGAAG CGGCGCGTGG TGAAGCGGCC CGTCGTGCGC TGCAGTATCT 
GAAAATTATG GCGGGCAGCA AA 
 
ACCRVLSELS EEQAFHVSYL DIEELSLSGL CQCLVELSTQ PATVCHGSAT 
TREAARGEAA RRALQYLKIM AGSK 	
TRBP-Ext-D3	(258-366):	
AATCGTGGCC CTGGTTGCAC CTGGGATAGC TTACGCAACA GCGTGGGTGA 
GAAAATTCTG AGTCTGCGCA GCTGCAGCCT GGGTAGCTTA GGTGCATTAG 
GCCCGGCATG TTGTCGTGTG CTGAGCGAGC TGAGCGAAGA ACAGGCCTTC 
CACGTGAGTT ACCTGGACAT CGAAGAGCTG AGTCTGAGCG GCCTGTGCCA 
GTGCCTGGTG GAGCTGAGCA CACAACCGGC AACAGTGTGT CACGGCAGTG 
CAACCACCCG CGAAGCAGCA CGCGGTGAAG CAGCACGTCG CGCACTGCAG 
TACCTGAAGA TTATGGCCGG CAGCAAG 
 
NRGPGCTWDS LRNSVGEKIL SLRSCSLGSL GALGPACCRV LSELSEEQAF 





IDYIKLLGEI ATENQFEVTY VDIEEKTFSG QFQCLVQLST LPVGVCHGSG 









11 uM, 22000 rpm 11 uM, 24000 rpm 11 uM, 42000 rpm
22 uM, 22000 rpm 22 uM, 24000 rpm 22 uM, 26000 rpm 22 uM, 33000 rpm
44 uM, 24000 rpm 44 uM, 26000 rpm 44 uM, 33000 rpm 44 uM, 42000 rpm
175 uM, 22000 rpm 175 uM, 33000 rpm 88 uM, 22000 rpm 88 uM, 33000 rpm
6.9 7.0 7.1 6.9 7.0 7.1 6.9 7.0 7.1
6.4 6.5 6.6 6.4 6.5 6.6 6.4 6.5 6.6 6.4 6.5 6.6
5.9 6.0 6.1 5.9 6.0 6.1 5.9 6.0 6.1 5.9 6.0 6.1






























































































11 uM, 22000 rpm 11 uM, 24000 rpm 11 uM, 42000 rpm
22 uM, 22000 rpm 22 uM, 24000 rpm 22 uM, 26000 rpm 22 uM, 33000 rpm
44 uM, 24000 rpm 44 uM, 26000 rpm 44 uM, 33000 rpm 44 uM, 42000 rpm
175 uM, 22000 rpm 175 uM, 33000 rpm 88 uM, 22000 rpm 88 uM, 33000 rpm
6.90 6.95 7.00 7.05 7.10 6.90 6.95 7.00 7.05 7.10 6.90 6.95 7.00 7.05 7.10 7.15
6.40 6.45 6.50 6.55 6.60 6.40 6.45 6.50 6.55 6.60 6.40 6.45 6.50 6.55 6.60 6.40 6.45 6.50 6.55 6.60
5.90 5.95 6.00 6.05 6.10 5.90 5.95 6.00 6.05 6.10 5.90 5.95 6.00 6.05 6.10 5.90 5.95 6.00 6.05 6.10




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































# Script to fit T1 and EXSY data of wild-type PACT-D3  
 
setwd("~/Dropbox/Phd/Data/Analysis/P3a")  # For Mac 
 
multiplot <- function(..., plotlist=NULL, file, cols=1, layout=NULL) { 
  # Multiplot function written by Winston Chang, and available from 
www.cookbook-r.com 
  require(grid) 
   
  # Make a list from the ... arguments and plotlist 
  plots <- c(list(...), plotlist) 
   
  numPlots = length(plots) 
   
  # If layout is NULL, then use 'cols' to determine layout 
  if (is.null(layout)) { 
    # Make the panel 
    # ncol: Number of columns of plots 
    # nrow: Number of rows needed, calculated from # of cols 
    layout <- matrix(seq(1, cols * ceiling(numPlots/cols)), 
                     ncol = cols, nrow = ceiling(numPlots/cols)) 
  } 
   
  if (numPlots==1) { 
    print(plots[[1]]) 
     
  } else { 
    # Set up the page 
    grid.newpage() 
    pushViewport(viewport(layout = grid.layout(nrow(layout), 
ncol(layout)))) 
     
    # Make each plot, in the correct location 
    for (i in 1:numPlots) { 
      # Get the i,j matrix positions of the regions that contain this 
subplot 
      matchidx <- as.data.frame(which(layout == i, arr.ind = TRUE)) 
       
      print(plots[[i]], vp = viewport(layout.pos.row = matchidx$row, 
                                      layout.pos.col = matchidx$col)) 
    } 




options = theme_bw() + theme(axis.text.x  = element_text(angle=90, 
vjust=0.5)) 
colours = scale_colour_brewer(palette="Set1")  
fills = scale_fill_brewer(palette="Set1") 
 
#### First, import, tidy and filter data #### 
# First import the raw T1 data 






t1_peaks = cbind(t1_peaks.raw[,1],stack(t1_peaks.raw[,3:20]))  # 
Convert to long format 
names(t1_peaks)=c("Assign","Height","t_mix") 
t1_peaks$t_mix = as.numeric(substring(t1_peaks$t_mix,2))/1000 
     # Convert text labels into times in s 
t1_peaks = cbind(parse_analysis_assignments(t1_peaks$Assign)[,-4], 
t1_peaks[,2:3]) 
t1_peaks$Height = t1_peaks$Height*100 # This just scales the heights 
from the t1 experiment to make them comparable to the EXSY 
t1_peaks = t1_peaks[!is.na(t1_peaks$Res.N),] 
names(t1_peaks)[1]="type" 
 
# Now import EXSY data 
exsy = rbind(cbind(read.delim("EXSY peak 
lists/EXSY_11.txt",na.strings="None", as.is=TRUE), t_mix=0.9), 
             cbind(read.delim("EXSY peak 
lists/EXSY_12.txt",na.strings="None", as.is=TRUE), t_mix=0.4), 
             cbind(read.delim("EXSY peak 
lists/EXSY_13.txt",na.strings="None", as.is=TRUE), t_mix=0.1), 
             cbind(read.delim("EXSY peak 
lists/EXSY_14.txt",na.strings="None", as.is=TRUE), t_mix=0.5), 
             cbind(read.delim("EXSY peak 
lists/EXSY_15.txt",na.strings="None", as.is=TRUE), t_mix=0.2), 
             cbind(read.delim("EXSY peak 
lists/EXSY_16.txt",na.strings="None", as.is=TRUE), t_mix=1.0), 
             cbind(read.delim("EXSY peak 
lists/EXSY_17.txt",na.strings="None", as.is=TRUE), t_mix=0.8), 
             cbind(read.delim("EXSY peak 
lists/EXSY_18.txt",na.strings="None", as.is=TRUE), t_mix=0.3), 
             cbind(read.delim("EXSY peak 
lists/EXSY_19.txt",na.strings="None", as.is=TRUE), t_mix=0.7), 
             cbind(read.delim("EXSY peak 
lists/EXSY_20.txt",na.strings="None", as.is=TRUE), t_mix=0.6)) 
 
exsy = cbind(parse_analysis_assignments(exsy$Assign.F1)[,c(1,2,5)], 
Chain.2=parse_analysis_assignments(exsy$Assign.F2)[,1], exsy[,c(-3,-
4)]) 
exsy$type = paste0(exsy$Chain.2, exsy$Chain) # Determine whether 
it's an auto peak (AA, BB) or an exchange peak (AB, BA) 
# Note that Chain.2 (the nitrogen assignment) is first, because the N 
frequency is measured before the mixing time 
 
#Make a dataframe containg the T1 and EXSY data 
names(t1_peaks)[1]="type" 
comb_data = rbind(exsy[,c(2,3,7,11,12)],t1_peaks[, c(2,4,5,6,1)]) 
comb_data = comb_data[!is.na(comb_data$Res.N),] # Remove NAs 
 
# Remove data which is affected by peak overlap 
exclude.1 = c(237, 240, 243, 244, 250, 256, 262,  
       266, 267, 269, 278, 290, 
293, 296, 300) # Peaks where neither auto- or cross-peaks are distinct 
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exclude.2 = c(239, 241, 242, 245, 246, 247, 248, 249, 
       251, 252, 253, 255, 259, 
263, 268, 271, 
       277, 289, 291, 292, 294, 
295, 297, 298, 
       303, 304, 307, 309) # Peaks 
where cross-peaks overlap auto-peaks 
comb_data = comb_data[!comb_data$Res.N %in% c(exclude.1, exclude.2),] 
 
exclude.3 = data.frame(Res.N=c(257, 265,275,283,284,286,299,308),  
       type.ex= 
c('BA','AB','AB','BA','AB','BA','BA','BA')) # Individual cross-peaks 
with overlaps 
tmp = merge(comb_data, exclude.3, by="Res.N", all.x=TRUE) 
comb_data = comb_data[tmp$type!=tmp$type.ex | is.na(tmp$type.ex),] 
 
exclude.4a = data.frame(Res.N=c(261,272,305,312), 
type.ex=c('A','A','B','A')) 
exclude.4b = data.frame(Res.N=c(261,272,305,312), 
type.ex=c('AA','AA','BB','AA')) # Individual auto-peaks with overlaps 
tmpa = merge(comb_data, exclude.4a, by="Res.N", all.x=TRUE) 
tmpb = merge(comb_data, exclude.4b, by="Res.N", all.x=TRUE) 
comb_data = comb_data[(tmpa$type!=tmpa$type.ex & 
tmpb$type!=tmpb$type.ex) | is.na(tmpa$type.ex),] 
 
exclude.5 = c(238, 270, 273, 301, 311) # Residues with no clear cross-
peaks 
comb_data=comb_data[!(comb_data$Res.N %in% exclude.5 & comb_data$type 
%in% c('AB','BA')),] 
 
exclude.6a = data.frame(Res.N=c(260,281,282,302,310), 
type.ex=c('A','B','B','A','A')) 
exclude.6b = data.frame(Res.N=c(260,281,282,302,310), 
type.ex=c('AB','AB','BA','AB','BA')) # Individual auto-peaks with 
overlaps 
tmpa = merge(comb_data, exclude.6a, by="Res.N", all.x=TRUE) 
tmpb = merge(comb_data, exclude.6b, by="Res.N", all.x=TRUE) 
comb_data = comb_data[(tmpa$type!=tmpa$type.ex & 
tmpb$type!=tmpb$type.ex) | is.na(tmpa$type.ex),] 
 
#### Test the fitting on a single residue #### 
active_residue = 313 
 
red_data = comb_data[comb_data$Res.N==active_residue,]  
ggplot(data=red_data[red_data$Res.N==active_residue,]) +  
 geom_point(aes(x=t_mix, y=Height, colour=type)) 
 
# First fit the case where R1_A = R1_B 
# According to Rule & Hitchens, peak intensities are given by: 
# I_AA(t) =  p_A * (p_A + p_B*exp(-k_ex*t)) * exp(-R1*t) 
# I_BB(t) =  p_B * (p_B + p_A*exp(-k_ex*t)) * exp(-R1*t) 
# I_AB(t) = I_BA(t) =  p_A * p_B * (1 - exp(-k_ex*t)) * exp(-R1*t) 
model1 <- nls(Height ~  (type=="AA")*I0*pA*(pA+(1-pA)*exp(-
k_ex*t_mix))*exp(-R1*t_mix) + 
        (type=="BB")*I0*(1-
pA)*((1-pA)+pA*exp(-k_ex*t_mix))*exp(-R1*t_mix) + 
        (type=="AB")*I0*pA*(1-
pA)*(1-exp(-k_ex*t_mix))*exp(-R1*t_mix) + 
        (type=="BA")*I0*pA*(1-
pA)*(1-exp(-k_ex*t_mix))*exp(-R1*t_mix) + 
       
 (type=="A")*I1*(pA*(pA+(1-pA)*exp(-k_ex*t_mix))*exp(-R1*t_mix) + 
           
   pA*(1-pA)*(1-exp(-k_ex*t_mix))*exp(-R1*t_mix)) + 
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        (type=="B")*I1*((1-
pA)*((1-pA)+pA*exp(-k_ex*t_mix))*exp(-R1*t_mix) +  
           
   pA*(1-pA)*(1-exp(-k_ex*t_mix))*exp(-R1*t_mix)), 
       data = 
red_data[red_data$Res.N==active_residue,],  
       start = list(I0=7e8, I1=5e8 
,pA=0.5, k_ex=0.6, R1=1.25), 
       algorithm="port",  # This 
algorithm allows setting upper and lower bounds 
       lower=c(1e8, 5e7, 0.3, 0.01, 
0.1), 
       upper=c(12e8, 5e9, 0.7, 5, 
2), 
      
 control=nls.control(warnOnly=TRUE), # setting warnOnly means 
that if a good fit can't be found, a fit will be returned anyway. 




fit=fitted(model1))) +  
 geom_point(aes(x=t_mix, y=Height, colour=type)) + 
 geom_line(aes(x=t_mix, y=fit, group=type, colour=type)) 
 
# And now the case where R1_A != R1_B 
# The below equations are from Farrow, Zhang, Forman-Kay, Kay (1994) J 
Bio NMR 
L1 = function(pA, rA, rB, k_ex) { 
  return( 0.5*(rA+rB+2*k_ex + sqrt((rA-rB)^2 + 4*k_ex^2)) ) 
} 
L2 = function(pA, rA, rB, k_ex) { 
  return( 0.5*(rA+rB+2*k_ex - sqrt( (rA-rB)^2 + 4*k_ex^2 )) ) 
} 
denom = function(pA, rA, rB, k_ex) { 
  return( L1(pA, rA, rB, k_ex) - L2(pA, rA, rB, k_ex) ) 
} 
I_AA = function(I0, pA, rA, rB, k_ex, t_mix) { 
  return( 
    I0*pA*(-(L2(pA, rA, rB, k_ex)-rA-k_ex)*exp(-L1(pA, rA, rB, 
k_ex)*t_mix) + 
             (L1(pA, rA, rB, k_ex)-rA-k_ex)*exp(-L2(pA, rA, rB, 
k_ex)*t_mix))/denom(pA, rA, rB, k_ex) 
  ) 
} 
I_BB = function(I0, pA, rA, rB, k_ex, t_mix) { 
  return( 
    I0*(1-pA)*(-(L2(pA, rA, rB, k_ex)-rB-k_ex)*exp(-L1(pA, rA, rB, 
k_ex)*t_mix) + 
             (L1(pA, rA, rB, k_ex)-rB-k_ex)*exp(-L2(pA, rA, rB, 
k_ex)*t_mix))/denom(pA, rA, rB, k_ex) 
  ) 
} 
I_AB = function(I0, pA, rA, rB, k_ex, t_mix) { 
  return ( 
    I0*pA*-k_ex*(exp(-L1(pA, rA, rB, k_ex)*t_mix) - exp(-L2(pA, rA, 
rB, k_ex)*t_mix))/denom(pA, rA, rB, k_ex) 
  ) 
} 
I_BA = function(I0, pA, rA, rB, k_ex, t_mix) { 
  return ( 
    I0*(1-pA)*-k_ex*(exp(-L1(pA, rA, rB, k_ex)*t_mix) - exp(-L2(pA, 
rA, rB, k_ex)*t_mix))/denom(pA, rA, rB, k_ex) 
  ) 
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} 
# Guess starting parameters 
I0_start = sum(red_data[red_data$Res.N==active_residue & red_data$type 
%in% c("AA","BB") & red_data$t_mix==0.1,"Height"]) 
I1_start = sum(red_data[red_data$Res.N==active_residue & red_data$type 
%in% c("A","B") & red_data$t_mix==0.01,"Height"]) 
pA_start = red_data[red_data$Res.N==active_residue & 
red_data$type=="A" & red_data$t_mix==0.01,"Height"]/I1_start 
#pA_start=0.6 
model2 <- nls(Height ~  (type=="AA")*I_AA(I0, pA, rA, rB, k_ex, t_mix) 
+ 
        (type=="BB")*I_BB(I0, 
pA, rA, rB, k_ex, t_mix) + 
        (type=="AB")*I_AB(I0, 
pA, rA, rB, k_ex, t_mix) + 
        (type=="BA")*I_BA(I0, 
pA, rA, rB, k_ex, t_mix) + 
        (type=="A")*(I_AA(I1, 
pA, rA, rB, k_ex, t_mix) + I_BA(I1, pA, rA, rB, k_ex, t_mix))+ 
        (type=="B")*(I_BB(I1, 
pA, rA, rB, k_ex, t_mix) + I_AB(I1, pA, rA, rB, k_ex, t_mix)), 
       data = 
red_data[red_data$Res.N==active_residue,],  
       start = list(I0=I0_start, 
I1=I1_start, pA=pA_start, k_ex=1.0, rA=0.8, rB=0.8), 
       #algorithm="port",  # This 
algorithm allows setting upper and lower bounds 
       #lower=c(1e6, 1e6, 0, 0.1, 
0.1, 0.1), 
       #upper=c(1e10, 1e10, 1, 10, 
10,10), 
      
 control=nls.control(warnOnly=TRUE), # setting warnOnly means 
that if a good fit can't be found, a fit will be returned anyway. 
       trace=FALSE) 
summary(model2) 
 
# Guess starting parameters 
I0_start = sum(red_data[red_data$Res.N==active_residue & red_data$type 
%in% c("AA","BB") & red_data$t_mix==0.1,"Height"]) 
I1_start = sum(red_data[red_data$Res.N==active_residue & red_data$type 
%in% c("A","B") & red_data$t_mix==0.01,"Height"]) 
pA_start = red_data[red_data$Res.N==active_residue & 
red_data$type=="A" & red_data$t_mix==0.01,"Height"]/I1_start 
#pA_start=0.6 
model3 <- nls(Height ~  (type=="AA")*I_AA(I0, pA, rA, rB, k_ex, t_mix) 
+ 
        (type=="BB")*I_BB(I0, 
pA, rA, rB, k_ex, t_mix) + 
        (type=="AB")*I_AB(I0, 
pA, rA, rB, k_ex, t_mix) + 
        (type=="BA")*I_BA(I0, 
pA, rA, rB, k_ex, t_mix), # + 
#        (type=="A")*(I_AA(I1, 
pA, rA, rB, k_ex, t_mix) + I_BA(I1, pA, rA, rB, k_ex, t_mix))+ 
#        (type=="B")*(I_BB(I1, 
pA, rA, rB, k_ex, t_mix) + I_AB(I1, pA, rA, rB, k_ex, t_mix)), 
       data = 
red_data[red_data$Res.N==active_residue,],  
       start = list(I0=I0_start, 
pA=pA_start, k_ex=1, rA=1, rB=1), 
#       algorithm="port",  # This 
algorithm allows setting upper and lower bounds 
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#       lower=c(1e6, 0, 0.1, 0.1, 
0.1), 
#       upper=c(1e10, 1, 10, 10,10), 
      
 control=nls.control(warnOnly=TRUE), # setting warnOnly means 
that if a good fit can't be found, a fit will be returned anyway. 




fit=fitted(model3))) +  
 geom_point(aes(x=t_mix, y=Height*(type %in% 
c("AA","BB","AB","BA"))+Height*(type %in% c("A","B")), colour=type)) + 
 geom_line(aes(x=t_mix, y=fit*(type %in% c("AA","BB","AB","BA")), 
group=type, colour=type)) 
 
#### Fit all residues where data is available #### 
models = list() 
fit_results = data.frame() 
 
# Exclude residues which have less than three EXSY cross peaks (on 
average) 
tmp = table(comb_data[comb_data$type %in% 
c('AA','BB','AB','BA'),c(1,4)]) 
tmp_list = unique(comb_data$Res.N) 
exclusions = tmp_list[rowMeans(tmp)<3] 
 
exclusions = c(exclusions, 285, 305, 312) # Also exclude residues 305 
and 312 due to peak overlap 
 
residue_list = setdiff(comb_data$Res.N, exclusions) 
 
starting_values = data.frame(Res.N=residue_list, I0=NA, I1=NA, pA=NA, 
rA=1, rB=1, k_ex=1) 
 
for (i in residue_list){ # For each residue 
 print(paste0("Fitting residue ",i,"...")) 
 # fit the model, catching any errors 
 # Guess starting parameters 
 I0_start = sum(comb_data[comb_data$Res.N==i & comb_data$type 
%in% c("AA","BB") & comb_data$t_mix==0.1,"Height"]) 
 I1_start = sum(comb_data[comb_data$Res.N==i & comb_data$type 
%in% c("A","B") & comb_data$t_mix==0.01,"Height"]) 
 pA_start = comb_data[comb_data$Res.N==i & comb_data$type=="A" & 
comb_data$t_mix==0.01,"Height"]/I1_start 
  
 if(length(c(I0_start, I1_start, pA_start))==3) { 
 starting_values[starting_values$Res.N==i, c("I0","I1","pA")] = 
c(I0_start, I1_start, pA_start) 
 } 
  
 m <- try(nls(Height ~  (type=="AA")*I_AA(I0, pA, rA, rB, k_ex, 
t_mix) + 
        (type=="BB")*I_BB(I0, pA, 
rA, rB, k_ex, t_mix) + 
        (type=="AB")*I_AB(I0, pA, 
rA, rB, k_ex, t_mix) + 
        (type=="BA")*I_BA(I0, pA, 
rA, rB, k_ex, t_mix) + 
        (type=="A")*(I_AA(I1, pA, 
rA, rB, k_ex, t_mix) + I_BA(I1, pA, rA, rB, k_ex, t_mix))+ 
        (type=="B")*(I_BB(I1, pA, 
rA, rB, k_ex, t_mix) + I_AB(I1, pA, rA, rB, k_ex, t_mix)), 
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       data = 
comb_data[comb_data$Res.N==i,],  
       start = list(I0=I0_start, 
I1=I1_start, pA=pA_start, k_ex=1, rA=1, rB=1), 
       #algorithm="port",  # This 
algorithm allows setting upper and lower bounds 
       lower=c(1e6, 1e6, 0, 0.1, 0.1, 
0.1), 
       upper=c(1e10, 1e10, 1, 10, 
10,10), 
       
control=nls.control(warnOnly=TRUE), # setting warnOnly means that if a 
good fit can't be found, a fit will be returned anyway. 
       trace=FALSE), silent=TRUE) 
 if (class(m)=="try-error"){ 
  # If there was an error, set all stored values to NA and 
move onto next residue 
  models=c(models,NA) 
  result = data.frame(Res.N=i, I0=NA, I1=NA, pA=NA,  
          rA=NA, rB=NA, 
k_ex=NA, 
          I0.lo=NA, 
I0.hi=NA,I1.lo=NA, I1.hi=NA, 
          pA.lo=NA, 
pA.hi=NA,rA.lo=NA, rA.hi=NA, 
          rB.lo=NA, 
rB.hi=NA,k_ex.lo=NA, k_ex.hi=NA, 
          
message1=geterrmessage(), message2=NA) 
  fit_results=rbind(fit_results, result) 
  next   
 } 
 # Calculate 95% confidence intervals, catching any errors 
 ci = try(confint(m), silent=TRUE) 
 if(class(ci)=="try-error") { 
  result = data.frame(Res.N=i, I0=coef(m)[["I0"]], 
I1=coef(m)[["I1"]], pA=coef(m)[["pA"]],  
          
rA=coef(m)[["rA"]], rB=coef(m)[["rB"]], k_ex=coef(m)[["k_ex"]], 
          I0.lo=NA, 
I0.hi=NA,I1.lo=NA, I1.hi=NA, 
          pA.lo=NA, 
pA.hi=NA,rA.lo=NA, rA.hi=NA, 
          rB.lo=NA, 
rB.hi=NA,k_ex.lo=NA, k_ex.hi=NA, 
          
message1=m$convInfo$stopMessage, message2=geterrmessage()) 
 } 
 else { 
  result = data.frame(Res.N=i, I0=coef(m)[["I0"]], 
I1=coef(m)[["I1"]], pA=coef(m)[["pA"]],  
        
 rA=coef(m)[["rA"]], rB=coef(m)[["rB"]], k_ex=coef(m)[["k_ex"]], 
        
 I0.lo=ci["I0",1], I0.hi=ci["I0",2],I1.lo=ci["I1",1], 
I1.hi=ci["I1",2], 
        
 pA.lo=ci["pA",1], pA.hi=ci["pA",2],rA.lo=ci["rA",1], 
rA.hi=ci["rA",2], 
        
 rB.lo=ci["rB",1], rB.hi=ci["rB",2],k_ex.lo=ci["k_ex",1], 
k_ex.hi=ci["k_ex",2], 
        
 message1=m$convInfo$stopMessage, message2=NA) 
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 } 
 # Store the model results 
 models=c(models,list(m)) 
 fit_results=rbind(fit_results, result) 
} 
 
# Export the fitted data 
write.table(fit_results, "Relaxation and EXSY/exported fits/full 
fit.txt", sep="\t", row.names=FALSE) 
 
#### Plot the results #### 
# Exclude residues where the model doesn't appear to fit the data well 
fit_results.filtered = fit_results[fit_results$message1%in%c("relative 
convergence (4)","converged"),] 






#### Try fitting a single exchange constant to all residues 
simultaneously #### 
# Based on a method from Miloushev et. al. (2008), Structure  
# This uses an approximation to remove the effects of differential 
relaxation rates for 1st and 2nd order in t. 
# Equation is Xi = (I_AB*I_BA)/(I_AA*I_BB - I_AB*I_BA) 
 
# Make an appropriate data frame 
global_data = comb_data[comb_data$type %in% c('AA','AB','BA','BB') & 
comb_data$Res.N %in% residue_list,] 
library(reshape2) 
tmp = melt(global_data, id.vars=c('Res.N','Res.name','t_mix','type'))  
# Puts the data into long format 
global_data = dcast(tmp, Res.N+Res.name+t_mix ~ type, 
value.var="value") # Put it back into wide format, with separate 
columns for AA,AB,BA and BB heights 
 
# Calculate Xi for each residue 
global_data$Xi = NA 
attach(global_data) 
global_data$Xi = (AB*BA)/(AA*BB-AB*BA) 
detach(global_data) 
global_data = global_data[!is.na(global_data$Xi),]  # Get rid of NA 
values 
global_data = global_data[global_data$Res.N %in% residue_list,]  # 
Restrict to the same residues used in the residue-by-residue analysis 
#global_data = global_data[global_data$t_mix<=0.5,] # Test restricting 
to early timepoints. This only marginally affects the exchange rate. 
 
# Fit Xi against t_mix^2, with no intercept or linear component 
global_fit = lm(Xi ~ 0 + I(t_mix^2), data=global_data) 
#[global_data$Res.N==313,]) 
k_ex.global = sqrt(coef(global_fit)) 
 
# Perform bootstrapping to find the error 
library(boot) 
stat = function(data, indices) { 
  d = data[indices,] 
  model = lm(Xi ~ 0 + I(t_mix^2), data=d) 
  return(sqrt(coef(model))) 
} 
 






Xi.model = data.frame(t_mix=x, 
Xi.pred=boot.obj$t0^2*x^2,Xi.lo=0.64^2*x^2, Xi.hi=0.79^2*x^2) 
 
#### Output pdfs of plots #### 
# Plot the EXSY/T1 fits for each residue 
for (i in 1:length(models)) { 
  if (!is.na(models[[i]])) { 
    pdf(paste0("Relaxation and EXSY/plots/exchange 
fits/",comb_data[comb_data$Res.N==residue_list[i],]$Res.name[1],".pdf"
), width=11.69/2, height=8.27/2, useDingbats=FALSE) 
    print( 
      ggplot(data=cbind(comb_data[comb_data$Res.N==residue_list[i],], 
fit=fitted(models[[i]]))) +  
        geom_point(aes(x=t_mix, 
y=Height/coef(models[[i]])[["I0"]]*(type %in% c("AA","BB","AB","BA"))+ 
                         Height/coef(models[[i]])[["I1"]]*(type %in% 
c("A","B")),  
                       colour=substr(type,1,1), 
shape=factor(nchar(type)))) + 
        geom_line(aes(x=t_mix, y= fit/coef(models[[i]])[["I0"]]*(type 
%in% c("AA","BB","AB","BA"))+ 
                        fit/coef(models[[i]])[["I1"]]*(type %in% 
c("A","B")),  
                      group=type, colour=substr(type,1,1), 
linetype=factor(nchar(type)))) + 
        xlab("Mixing time (s)") + ylab("Relative peak height") + 
        ggtitle(paste("Raw data and fitted values for 
residue",residue_list[i])) + 
        scale_colour_brewer(name="Chain", palette="Set1") +  
        scale_linetype_discrete(name="Experiment", labels=c("T1", 
"EXSY")) + 
        scale_shape_discrete(name="Experiment", labels=c("T1", 
"EXSY")) + 
        theme_bw() 
    ) 
    dev.off() 
  } 
} 
 
# Plot various parameters from the T1/EXSY fits, with poorly fitting 
residues excluded 
pdf(paste0("Relaxation and EXSY/plots/Exchange rate plot (combined 
EXSY,T1 fit).pdf"), height=11.69/4, width=8.27/2, useDingbats=FALSE)  
print( 
  ggplot(data=fit_results.filtered, aes(x=factor(Res.N))) + 
geom_bar(aes(y=k_ex), stat="identity") +  
    geom_errorbar(aes(ymin=pmax(k_ex.lo, 0.1, na.rm=TRUE), 
ymax=pmin(k_ex.hi,10,na.rm=TRUE)), width=.5) + 
    xlab("Residue") + ylab("Exchange rate (/s)") +  
    ggtitle("Fitted exchange rate with 95% confidence intervals") + 




pdf(paste0("Relaxation and EXSY/plots/T1 plot (combined EXSY,T1 
fit).pdf"), height=11.69/4, width=8.27/2, useDingbats=FALSE)  
print( 
  ggplot(data=fit_results.filtered, aes(x=factor(Res.N))) +  
    geom_point(aes(y=1/rA, colour="A"), size=3) + 
geom_point(aes(y=1/rB, colour="B"), size=3) +  
	 214	
    geom_errorbar(aes(ymin=1/pmax(rA.lo, 0.1, na.rm=TRUE), 
ymax=1/pmin(rA.hi,10,na.rm=TRUE), colour="A", width=.5)) + 
    geom_errorbar(aes(ymin=1/pmax(rB.lo, 0.1, na.rm=TRUE), 
ymax=1/pmin(rB.hi,10,na.rm=TRUE), colour="B", width=.5)) + 
    xlab("Residue") + ylab("T1 (s)") + 
    ggtitle("Fitted T1 relaxation time with 95% confidence intervals") 
+ 
    coord_cartesian(ylim=c(0, 2)) + scale_colour_brewer(name="Chain", 




pdf(paste0("Relaxation and EXSY/plots/Population plot (combined 
EXSY,T1 fit).pdf"), width=11.69, height=8.27/2, useDingbats=FALSE)  
print( 
  ggplot(data=fit_results.filtered, aes(x=factor(Res.N))) +  
    geom_bar(aes(y=pA), stat="identity") +  
    geom_errorbar(aes(ymin=pmax(pA.lo, 0, na.rm=TRUE), 
ymax=pmin(pA.hi,1,na.rm=TRUE), width=.5)) + 
    xlab("Residue") + ylab("Fractional population of state A") + 
    ggtitle("Fractional population of state A with 95% confidence 
intervals") + 
    coord_cartesian(ylim=c(0, 1)) + scale_colour_brewer(name="Chain", 




# Plot results from the global fit 
pdf("Relaxation and EXSY/plots/Global fit of EXSY data.pdf", 
width=8.27/2, height=8.27/2, useDingbats=FALSE) 
print( 
  ggplot() + geom_ribbon(data=Xi.model, aes(x=t_mix, ymax=Xi.hi, 
ymin=Xi.lo), alpha=0.25) +  
    geom_point(data=global_data, aes(x=t_mix, y=Xi, colour=Res.name), 
alpha=0.75) +  
    geom_line(data=Xi.model, aes(x=t_mix, y=Xi.pred)) + xlab("Mixing 
time (s)") + ylab("Composite parameter Xi") + 
    ggtitle(paste0("Global fit of exchange rate = ", 
format(k_ex.global, digits=3)," /s")) + 








Dissecting the roles of TRBP and
PACT in double-stranded RNA
recognition and processing of
noncoding RNAs
Alex Heyam,1 Dimitris Lagos2 and Michael Plevin1∗
HIV TAR RNA-binding protein (TRBP) and Protein Activator of PKR (PACT)
are double-stranded (ds) RNA-binding proteins that participate in both small
regulatory RNA biogenesis and the response to viral dsRNA. Despite considerable
progress toward understanding the structure–function relationship of TRBP and
PACT, their specific roles in these seemingly distinct cellular pathways remain
unclear. Both proteins are composed of three copies of the double-stranded
RNA-binding domain, two of which interact with dsRNA, while the C-terminal
copy mediates protein–protein interactions. PACT and TRBP are found in a
complex with the endonuclease Dicer and facilitate processing of immature
microRNAs. Their precise contribution to the Dicing step has not yet been
defined: possibilities include precursor recruitment, rearrangement of dsRNA
within the complex, loading the processed microRNA into the RNA-induced
silencing complex, and distinguishing different classes of small dsRNA. TRBP and
PACT also interact with the viral dsRNA sensors retinoic acid-inducible gene I
(RIG-I) and double-stranded RNA-activated protein kinase (PKR). Current models
suggest that PACT enables RIG-I to detect a wider range of viral dsRNAs, while
TRBP and PACT exert opposing regulatory effects on PKR. Here, the evidence
that implicates TRBP and PACT in regulatory RNA processing and viral dsRNA
sensing is reviewed and discussed in the context of their molecular structure.
The broader implications of a link between microRNA biogenesis and the innate
antiviral response pathway are also considered. © 2015 John Wiley & Sons, Ltd.
How to cite this article:
WIREs RNA 2015. doi: 10.1002/wrna.1272
INTRODUCTION
Double-stranded (ds) RNA has a vital role innormal cellular function. Any structured RNA,
such as the ribosome, contains regions of dsRNA,
which are often part of higher order tertiary struc-
ture. In addition, dsRNA is an intermediate in the
biogenesis of short regulatory RNAs such as micro
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2Centre for Immunology and Infection, University of York, York,
UK
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RNAs (miRNAs), endogenous short interfering RNAs
(siRNAs), and Piwi-interacting RNAs (piRNAs).1
However, dsRNA is also an important replica-
tion intermediate for RNA viruses, for instance SARS
coronavirus, poliovirus, and hepatitis C virus. It is cru-
cial for cells to distinguish cellular dsRNA from viral
dsRNA, and respond appropriately. Differentiation of
self versus non-self dsRNA is achieved by proteins that
have evolved to recognize chemical features specific to
viral dsRNA, such as terminal 5′ triphosphate groups.
These proteins are termed pattern recognition recep-
tors (PRRs), and include TLRs (Toll-like receptors)
3, 7, and 8; RIG-I (retinoic acid-inducible gene I);
© 2015 John Wiley & Sons, Ltd.
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and MDA5 (melanoma differentiation associated
protein 5).2
The closely related mammalian proteins TRBP
[HIV trans-activation responsive (TAR) RNA-binding
protein; HGNC symbol, TARBP2; UniProt, Q15633]
and PACT (Protein Activator of PKR; PRKRA;
O75569) bridge several of these pathways (Figure 1(a)
and (b)). TRBP was initially identified through its
interaction with the HIV TARRNA element, and both
proteins were found to regulate the response to viral
dsRNA through the protein PKR (double-stranded
RNA-activated protein kinase; EIF2AK2).3,4 Subse-
quently, TRBP and PACT were shown to interact with
Dicer (DICER1), the ribonuclease responsible for
processing the precursors of miRNAs and siRNAs.5,6
More recently, PACT has been shown to activate
RIG-I (DDX58), another innate immune sensor of
viral RNA.7 However, these different roles are often
studied independently, and the links between them
remain largely unexplored.
This review will summarize current knowledge
about TRBP and PACT, and how they influence small
RNA biogenesis and viral sensing.
TRBP AND PACT EACH CONTAIN
THREE DOUBLE-STRANDED
RNA-BINDING DOMAINS
TRBP and PACT each contain three double-stranded
RNA-binding domains (dsRBDs) that are separated
by unstructured linker regions8,9 (Figure 1(c)). Many
RNA-binding proteins contain multiple dsRBDs:
PKR, ADAR2, and DGCR8 all have tandem dsRBDs,
while human Staufen has five.10–13 The presence of
multiple dsRBDs in the same protein is thought to
allow greater affinity and specificity, and to allow
functional divergence of individual domains.14,15
Although all dsRBDs share the core 훼-훽-훽-훽-훼
fold (Figure 2), they can be divided into two sub-
groups depending on sequence conservation. The type
A dsRBD is the canonical form, which shows amino
acid conservation in three regions involved in dsRNA
binding (Figure 2(a)). Type B dsRBDs show conserva-
tion only at the C-terminal end of the domain, and
are generally unable to bind dsRNA, despite retaining
the same overall three-dimensional (3D) structure.8,18
PACT and TRBP contain both classes of dsRBD
(Figure 2(a)).
Some dsRBDs have additional structural ele-
ments that contribute to their function: for example,
Rnt1p dsRBD from Saccharomyces cerevisiae has an
additional 훼-helix that contributes to domain sta-
bility and RNA binding,19 while dsRBDs from the
Caenorhabditis elegans TRBP homolog, RDE-4, have
recently been shown to contain numerous additional
helixes and extended loop regions20 (see Box 1).
BOX 1
HOMOLOGS OF TRBP AND PACT:
C. elegans RDE-4
C. elegans RDE-4 forms a complex with homologs
of Dicer and Argonaute, and is required for
dsRNA-mediated RNA interference (RNAi), but
not miRNA-mediated silencing.21 RDE-4 contains
three dsRBDs and binds nonspecifically to dsRNA,
with an affinity for siRNA similar to that reported
previously for TRBP.22–24 The first two dsRBDs
appear to function independently, with the sec-
ond having a higher affinity for dsRNA, as was
shown for TRBP.20,22 RDE-4 has a higher affinity
for longer dsRNAs, which may be due to cooper-
ative binding, or an effect related to the overlap
in potential binding sites.
As in TRBP and PACT, the C-terminal dsRBD
of RDE-4 is required for interaction with Dicer,
and also mediates dimerization.24 In addition,
the linker between domains 1 and 2 is required
for dsRNA processing by Dicer.25 The first two
dsRBDs of RDE-4 have additional structural ele-
ments that extend into this linker region.20 It will
be interesting to see how these additional ele-
ments affect the function of the domains—it has
already been shown that domain 1 is required for
binding siRNAs, while having only a small influ-
ence on binding to longer dsRNA.25
TRBP and PACT Domains 1 and 2 Bind
dsRNA
Domains 1 and 2 of both TRBP and PACT are
type A dsRBDs, and all bind dsRNA.22,26 In type A
dsRBDs, three distinct regions participate in dsRNA
binding (Figure 2(a) and (b)). Unlike dsDNA, dsRNA
adopts an A form helix in which the major groove
is deep and narrow, limiting access to the bases and
therefore to sequence-specific information. dsRBDs
bind across two adjacent minor grooves and the
intervening phosphate backbone, burying ∼780Å2 of
the domain surface. In general, it is thought that
dsRBDs bind nonspecifically to dsRNA. On discovery,
TRBP was thought to specifically recognize certain
structured RNAs, such as HIV-1 TAR RNA27,28;
however, later evidence has shown that TRBP and
PACT interact with a broad range of targets.22,23
However, several well-studied dsRBD-
containing proteins do act on specific targets. For
example, Staufen can regulate translation and decay
© 2015 John Wiley & Sons, Ltd.

































































FIGURE 1 | Functions and domain composition of TAR RNA-binding protein (TRBP) and Protein Activator of PKR (PACT). (a) Precursor
(pre-)microRNAs (miRNAs) are RNA hairpins that are produced in the nucleus, and exported to the cytoplasm. They contain the ∼22 nt sequence of
the mature miRNA, indicated in red. The endonuclease Dicer removes the terminal loop to give an RNA duplex, one strand of which is loaded into an
Argonaut (Ago) protein to form RNA-induced silencing complex (RISC). TRBP and PACT are implicated in both Dicing and RISC loading. (b) PACT and
TRBP have roles in at least two viral response pathways. First, PACT can facilitate activation of retinoic acid-inducible gene I (RIG-I) by viral
double-stranded RNA (dsRNA) (distinguished from cellular dsRNA by distinct molecular features, discussed in section TRBP and PACT mediate innate
immune surveillance). This begins a signaling cascade that results in the production of interferon and other antiviral genes. PACT and TRBP also
regulate PKR, a kinase that targets the translation initiation factor eIF2훼 to inhibit protein production and promote apoptosis. TRBP inhibits PKR,
while PACT can activate it in response to cellular stress. (c) Both PACT and TRBP contain three double-stranded RNA-binding domains (dsRBDs). The
first two domains can bind dsRNA, while the third cannot. Interactions with many other proteins have been documented, particularly for the third
domain. Solid lines indicate direct protein–protein interactions, while dashed lines indicate interactions that may be mediated via dsRNA. The third
dsRBD potentially has an N-terminal extension, based on sequence conservation. Each protein has a number of phosphorylation sites (marked by
yellow triangles) that regulate function under certain conditions. A region of TRBP implicated in cancers exhibiting microsatellite instability is
indicated in red.










FIGURE 2 | (a) Sequence alignment of the double-stranded RNA-binding domains (dsRBDs) of TAR RNA-binding protein (TRBP) and Protein Activator of PKR (PACT). The top line shows the secondary
structure of a ‘typical’ dsRBD, taken from the three-dimensional (3D) structure of TRBP domain 2 (PDB accession: 3ADL). Residues conserved between all domains are highlighted in black; those
conserved between domains 1 and 2 are highlighted in dark gray; while those conserved in the third domain are shown in light gray. The regions of domains 1 and 2 that bind RNA [located in helix 훼1,
the loop between 훽 strands 1 and 2 (loop-훽12), and helix 훼2] are boxed, as is a conserved region upstream of domain 3, which may represent a structural element additional to the standard dsRBD fold.
On the right, the % identity (% similarity) shows that equivalent dsRBDs between TRBP and PACT are more similar than dsRBDs within the same protein. The sequences were aligned using Multalin,16
and rendered using ESPript17 (http://espript.ibcp.fr). (b) Two views of TRBP-D2 bound to two molecules of 10 bp double-stranded RNA (dsRNA) (PDB accession 3ADL). The RNA-interacting regions shown
in part (a) are highlighted. Several parts of the dsRNA-binding interface are flexible, most notably loop-훽12 in the second RNA-interacting region, which contains a highly conserved histidine residue. (c)
Structure of a Staufen-D5 dimer (PDB accession 4DKK). The N-terminal extension (consisting of two 훼-helixes) is thought to interact with the dsRBD core of a second molecule. The linker between the
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of specific mRNAs, while ADAR proteins can convert
adenosine to inosine at precise positions in a variety
of dsRNAs.29,30 In both cases, RNA recognition is
believed to occur through tertiary structures, such as
bulges and loops.19,31 Some specificity may also arise
through contact with the edges of bases in the minor
groove, and through the combination of dsRBDs with
weak sequence or secondary structure preferences.15,18
Current evidence does not rule out PACT and TRBP
having a degree of substrate specificity.
TRBP and PACT Bind Protein Partners
Primarily via Their Third Domain
The C-terminal dsRBDs of both TRBP and PACT
(hereafter referred to as TRBP-D3 or PACT-D3) are
type B dsRBDs. They do not bind RNA, but are
instead required for interaction with other proteins.
It is thought that many type B dsRBDs mediate
protein–protein interactions: for example,Drosophila
Staufen domain 5 binds to Miranda to enable mRNA
localization.32,33 However, currently, there is no struc-
tural information available about how dsRBDs inter-
act with other proteins.
Both PACT-D3 and TRBP-D3 bind to
Dicer,5,6,34,35 while PACT-D3 has also been shown
to interact with the virus-sensing protein PKR.7,9
TRBP-D3 is not thought to interact with PKR,36
suggesting that binding to Dicer and PKR is mediated
by different regions of PACT-D3. These interactions
are discussed further in sections TRBP and PACT
Form Part of the Small RNA Biogenesis Pathway and
TRBP and PACT Mediate Innate Immune Surveil-
lance of dsRNA below. Other binding partners have
been suggested for TRBP and PACT, such as the
tumor suppressor Merlin,37 but the nature of their
interactions has not yet been studied in detail.
Although several dsRBDs have been reported
to dimerize (e.g., the dsRBDs from PKR38 and
ADAR239), it has been difficult to distinguish
between direct binding and indirect association via
dsRNA.40 There is substantial biochemical evidence
that PACT-D3 can homodimerize or heterodimerize
with TRBP-D3.41–43 While there is no direct bio-
physical evidence that TRBP-D3 homodimerizes,
full-length TRBP can form dimers,23 though a con-
struct lacking TRBP-D3 does not.22 Dimerization
of PACT and TRBP has been suggested to modulate
PACT activation of PKR,43 but could also increase
their affinity for dsRNA, by bringing together four
type A dsRBDs.26
The recent 3D structure of dsRBD 5 of Staufen
(Staufen-D5) gave the first high-resolution informa-
tion about a dsRBD dimer32 and revealed several
features that distinguish type B dsRBDs, including
the absence of the conserved histidine residue in
loop-훽1,2, the presence of large negatively charged
patches on the canonical dsRNA-binding surface,
and a region of extra-dsRBD structure, which is
required for dimerization. As the linker between
the core domain and the extended region is flexi-
ble, it was proposed that dimerization occurs via a
domain-swapping mechanism (Figure 2(c)).
TRBP-D3 and PACT-D3 both lack the key his-
tidine residue and have negatively charged residues
at sites that would correspond to the dsRNA-binding
surface. Furthermore, both domains are preceded by
a highly conserved 20 amino acid sequence, which
may suggest a similar dsRBD/dsRBD interaction to
that seen in Staufen-D5. Interestingly, the conserved
residues between TRBP-D3 and PACT-D3 are pre-
dicted to cluster on the opposite surface to the typical
dsRNA-binding face, which potentially suggests the
location of a conserved protein interaction site.
There is also evidence that the type A dsRBDs
of TRBP and PACT mediate protein–protein inter-
actions. Domains 1 and 2 of PACT are reported to
directly interact with the dsRBDs of PKR.9,44 PKR also
dimerizes partly through its dsRBDs,38 and PACT can
still activate PKR if its first two domains are replaced
with those from PKR.9 The first two dsRBDs of PACT
and TRBP have also been reported to homodimer-
ize and heterodimerize,41,43 which suggests there may
be a common dimerization mechanism between these
domains. However, current evidence does not exclude
the possibility that these interactions are indirect or
mediated by dsRNA.
TRBP AND PACT FORM PART OF THE
SMALL RNA BIOGENESIS PATHWAY
RNAi is a highly conserved process (see Figure 1(a))
in which short RNA molecules cause translational
(or transcriptional) silencing of complementary mes-
senger RNAs (mRNAs). The cellular pathways that
underpin RNAi have been discussed in detail by sev-
eral recent reviews.1,45,46 Here, we will provide only a
brief summary of RNAi in mammals.
Somatic cells contain two major classes of
small regulatory RNA: miRNA and siRNA. Both
are approximately 22 nt long, but differ in their bio-
genesis and target recognition. miRNAs are derived
from RNA hairpins that usually contain several
mismatched bases, while siRNAs are processed from
longer dsRNA molecules. siRNAs are typically highly
complementary to their targets, whereas miRNAs
require a 6–8 nt ‘seed’ region to be perfectly matched,
with other positions contributing only weakly to
target specificity. Although there are relatively few
© 2015 John Wiley & Sons, Ltd.
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reports of endogenous mammalian siRNAs, dsRNA
can be introduced exogenously either as RNA hairpins
(shRNA) or as short dsRNA duplexes.
In the canonical miRNA biogenesis pathway,
miRNAs are transcribed as long primary (pri-)
miRNAs that contain a 60–80 nucleotide hairpin
structure. The pri-miRNA is processed in the nucleus
by Drosha/DGCR8 (the ‘microprocessor’ complex) to
a shorter precursor (pre-) miRNA. The pre-miRNA is
exported from the nucleus by Exportin 5, and further
cleaved by a protein complex containing the ribonu-
clease Dicer, one of four Argonaute proteins (Ago1–4),
and either TRBP or PACT (Figure 3(a)–(c)). This sec-
ond processing step removes the terminal hairpin
loop, leaving an RNA duplex of ∼22 bp in length.
One strand of the dsRNA Dicer product
is removed, while the other (the guide strand) is
loaded into Argonaute. This Ago:miRNA complex,
together with its protein partners, is referred to as
the RNA-induced silencing complex (RISC). Despite
recent progress, the mechanism of strand-selective
RISC loading remains to be determined47,48; how-
ever, many miRNAs can contribute either strand to
RISC.49 Once loaded, the guide strand targets RISC
to complementary mRNAs, which results in either
suppression of translation, enhanced degradation
and/or cleavage of the mRNA. Although only Ago2
has the ability to cleave mRNAs, miRNAs and siR-
NAs appear to distribute among all four Argonautes
with little specificity.50,51
How Do TRBP and PACT Affect Processing
by Dicer and the Formation of Active RISC?
There is now clear evidence that TRBP and PACT
can associate with Dicer, both from immunoprecipita-
tion experiments5,6,35,52,53 and from in vitro reconsti-
tution of the complex from the individually purified
components.54,55 Furthermore, there is strong sup-
port for the idea that PACT and TRBP are involved
in processing of pre-miRNAs and RISC loading.5,58
However, the molecular mechanism by which TRBP
and PACT facilitate miRNA and siRNA processing
remains unclear. It has long been established that Dicer
alone is able to cleave pre-miRNA to mature miRNA
in vitro,56 and there is evidence that some substrates
can be loaded into Ago2 in vitro in the absence of
TRBP or PACT.48,57,58
The importance of tackling this question is
underscored by the evidence linking miRNA biogen-
esis in general, and TRBP in particular, to a number of
different cancers.64–68 In particular, tumors exhibiting
microsatellite instability are prone to frameshift muta-
tions in TRBP (see Figure 1(c)), leading to impaired
FIGURE 3 | (a) Layout of domains within Dicer. (b) Reconstruction
of the Dicer–TAR RNA-binding protein (TRBP) complex from
cryo-electron microscopy (EM) data, with ∼15 Å resolution (EM data
bank accession EMD-1646).59 The locations of the RNase III and
helicase domains are inferred from epitope-tagged Dicer.60 The position
of TRBP is not resolved. (c) A schematic of a minimal RNA-induced
silencing complex (RISC)-loading complex of Dicer, Ago2, and
TRBP/PACT (Protein Activator of PKR) based on cryo-EM data.61 All
components are approximately to scale. It is unknown whether all three
components assemble prior to double-stranded RNA (dsRNA) binding,
or if the complex is more dynamic. In vivo, it is likely that other proteins
associate with the RISC-loading complex.62,63 (d) At least four possible
roles for TRBP/PACT can be envisaged (see section How Do TRBP and
PACT Affect Processing by Dicer and the Formation of Active RISC?): (1)
TRBP/PACT may help recruit dsRNA to Dicer; (2) TRBP/PACT may aid
alignment of dsRNA for cleavage by Dicer; (3) TRBP/PACT may help
dsRNA unwinding and/or loading into Argonaute proteins; or (4)
TRBP/PACT may favor processing and loading of different substrates
into RISC (the substrates shown are illustrative only).
© 2015 John Wiley & Sons, Ltd.
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miRNA production.65 The drug enoxacin has recently
been investigated as a cancer therapeutic owing to
its effect on miRNA biogenesis, and is believed to
act through TRBP.69,70 Although several studies have
linked PACT expression to cancer, the effect is not as
well documented as for TRBP.71,72
There are several points along the miRNA bio-
genesis and RISC loading pathway at which TRBP and
PACT could act (see also Figure 3(d)):
(1) Recruitment of substrates to Dicer
(a) TRBP and/or PACT may increase the affin-
ity of the Dicer complex for dsRNA, or
(b) more specifically increase Dicing rate
through favoring binding of substrates
over products.
(2) Facilitating efficient substrate cleavage by Dicer
TRBP and/or PACT could ensure that the sub-
strate dsRNA or pre-miRNA has the optimum
orientation for Dicer cleavage.
(3) Removing the Dicer product
(a) TRBP and/or PACT may aid unloading of
Dicer or loading of Dicer products into
Argonaute proteins,
(b) in particular affecting which strand is
loaded.
(4) Controlling which type of dsRNA is loaded into
Argonaute
TRBP and/or PACT may preferentially recog-
nize different subsets of miRNA or siRNA (or
their precursors), resulting in differences in
processing or RISC loading.
We will now discuss evidence from structural,
biochemical, biophysical, and molecular cell biology
studies in the context of these possible mechanisms.
Evidence from Structural Studies
As described above, TRBP and PACT have been
shown to interact with Dicer, a 1922-amino acid type
III ribonuclease (Figure 3). The mechanism by which
Dicer controls the length of small RNAs was elegantly
resolved in an early crystallographic study.59,73 The
Dicer PAZ domain binds one end of the pre-miRNA,
while a ‘ruler’ domain positions the PAZ domain at
a distance from the RNase III site that corresponds to
roughly 22 base pairs of dsRNA. This simple struc-
tural mechanism appears to function independently
of binding partners as isolated Dicer can still cleave
dsRNA targets.
While a considerable amount is known about the
structure–function relationship of the RNase III/PAZ
region of Dicer, much less is known about the
N-terminal DExD/H helicase domain. The helicase
domain consists of Hel1 and Hel2 regions separated
by a 100-amino acid insert region (Figure 4(a)), which
has no sequence homologs outside of the Dicer fam-
ily. Yeast-2-hybrid screens have identified the insert
region as the site of TRBP (and presumably PACT)
binding.35 This domain does not appear necessary for
dsRNA cleavage in vitro,74 nor does processing of
pre-miRNAs require ATP.75
Atomic resolution structures of larger constructs
of human Dicer or complexes containing TRBP or
PACT are not currently available. The 20–30Å res-
olution cryo-electron microscopy studies of a Dicer
alone,60 in complex with TRBP,59 or TRBP and
Ago2 (a minimal RISC-loading complex)61 have been
reported. They reveal an L-shaped overall structure
with the helicase located in the base, and the RNase III
and PAZ domains located in the long arm. However,
these studies have been unable to identify precisely
where and how TRBP interacts with Dicer.
Because only the C-terminal domains (CTDs)
of TRBP or PACT bind to Dicer, it appears likely
that domains 1 and 2 have considerable freedom of
movement, consistent with roles 1–3 outlined above.
To exclude proposed roles for TRBP, it will be nec-
essary to determine more precisely where it interacts
with Dicer. Similarly, a greater understanding of how
flexible TRBP remains when bound to Dicer and
dsRNA would allow possible roles to be considered
or discounted. It is worth noting that several papers
have suggested that Dicer and/or associated proteins
undergo conformational shifts61,76 and that these
complexes contain multiple dsRNA-binding sites.77
This raises the possibility that the role of TRBP may
be more complex than currently believed.
Evidence from Biochemical and Biophysical
Studies
A number of in vitro studies have shown that the
complex of Dicer with TRBP or PACT has a higher
affinity for dsRNA than Dicer alone by several orders
of magnitude.55,78,79 However, these studies report a
more modest effect on small RNA processing rate,
ranging from a fivefold increase in processing rate to
a fivefold reduction. With the caveat that the reaction
conditions may differ considerably from those present
in vivo, this suggests TRBP and PACT fulfill role
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FIGURE 4 | (a) In the absence of appropriate ligands, retinoic acid-inducible gene I (RIG-I) has an inactive conformation, in which the helicase
domain binds to the caspase recruitment domains (CARDs). 5′-Triphosphate double-stranded RNA (dsRNA) binds to the C-terminal domain (CTD) and
helicase domain, which displaces the CARDs and results in signaling. It is less clear how Protein Activator of PKR (PACT) enables RIG-I activation: one
possibility is that it increases RIG-I binding to additional ligands such as long dsRNA that lacks a 5′-triphosphate. (b) PKR can bind to long dsRNA
through two N-terminal double-stranded RNA-binding domains (dsRBDs). This brings PKR molecules together to form dimers, which can then
autophosphorylate and become active. PACT (when phosphorylated during cellular stress) can also activate PKR, although the mechanism is unclear.
The two main hypotheses are: PACT-D3 contacts the kinase domain, somehow favoring activation, or PACT dimers can bind two molecules of PKR,
promoting their dimerization and activation. TRBP acts as an inhibitor of PKR, either because its third domain cannot interact with PKR’s kinase
domain or because its third domain exhibits weaker dimerization.
1a above, but not 1b. Furthermore, TRBP has been
reported to bind a pre-miRNA and the duplex Dicer
product with similar affinities,22,55 which is inconsis-
tent with a role in modulating Dicer processing rate
due to preferential binding of substrate over product.
The measured affinity of TRBP (without Dicer)
for short dsRNA has varied considerably between
different studies.22,23,55 While this may simply repre-
sent variation in sample preparation and technique, it
could also be due to the different RNAs studied, which
would be consistent with TRBP and PACT showing a
degree of specificity for different small RNAs (role 4).
Additional evidence comes from studies of recon-
stituted complexes of Dicer. Dicer/TRBP complexes
show different affinities for different pre-miRNAs and
siRNAs, although Dicer itself is at least partially
responsible for this specificity.55,78 A complex contain-
ing Dicer and PACT showed considerably slower pro-
cessing of short dsRNA substrates than a Dicer/TRBP
complex, even though they seemed to have similar
processing rates for pre-miRNAs.79 These data poten-
tially conflict with an earlier study, which concluded
that both PACT and TRBP increase processing of long
dsRNAs by Dicer.80 This discrepancy could reflect
© 2015 John Wiley & Sons, Ltd.
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a genuine difference in how Dicer complexes pro-
cess dsRNAs of different lengths; further experiments
using matched reaction conditions will be required to
resolve this issue.
Both in vitro and in vivo, cleavage of
pre-miRNAs by Dicer can give a range of prod-
ucts with different lengths, termed iso-miRs.81,82
The size distribution of iso-miRs varies depending
on the pre-miRNA. The Dicer/TRBP complex pro-
duces different length products compared with Dicer
alone,82,83,78,79 supporting the idea that TRBP helps
position RNA for cleavage by Dicer (role 2). PACT has
not yet been observed to affect iso-miR distribution.
In Drosophila, current models suggest that the
TRBP homolog R2D2 (see Box 2) plays a significant
role in selecting which strand of the miRNA/siRNA
is loaded into Argonaute. There is some evidence that
this is also the case in humans. The thermodynamic
stability of the miRNA or siRNA duplex produced
BOX 2
RNA INTERFERENCE IN D. melanogaster
Drosophila melanogaster has emerged as an
important model system for research into RNAi,
often revealing interactions and mechanisms
that are later shown to occur in humans. Unlike
mammals, Drosophila uses siRNA as an antivi-
ral defense, termed exogenous (exo-) siRNA.85
In addition, an endogenous (endo-) siRNA path-
way exists to targetmobile genetic elements.86 In
general, themiRNApathway utilizes the proteins
Dicer-1 and Ago1, while siRNA pathways rely on
Dicer-2 and Ago2.87
Several TRBP homologs have been iden-
tified in Drosophila, most notably the proteins
R2D2 and Loquacious (Loqs). R2D2 forms a
complex with Dicer-2 and assists strand-specific
loading of siRNA into Ago2,88,89 while Loqs
plays a role in processing of pre-miRNAs by
Dicer-1.90,91 At least four isoforms of Loqs have
been identified, which differentially process
specific miRNAs, lead to altered iso-miR distri-
butions, and even interact with different Dicer
proteins.83,92,93 At the whole organism level,
reduction of Loqs expression causes infertil-
ity owing to terminal differentiation of germ
cells, while complete knockout is lethal.83,94,95
While TRBP and PACT share several properties
with Drosophila dsRBPs,78,96 currently, there is
no clear evidence for a similar delineation of
function on the protein level in the mammalian
system.
by Dicer is dependent on the nucleotide sequence.
Experiments with photo-cross-linking dsRNA con-
cluded that TRBP has some propensity to bind
to the most thermodynamically stable end of the
siRNA.47 Furthermore, strand-specific crosslinking to
the helicase domain of Dicer required TRBP or PACT
and depended on thermodynamic stability, terminal
nucleotides, andmismatched bases.77 However, strand
selectivity is not solely determined at this step: a study
that measured which strand was loaded into RISC
concluded that Ago2 alone had some strand selectiv-
ity (dependent on substrate), though TRBP and PACT
could enhance this.48
Lastly, it has recently been shown that TRBP can
diffuse along dsRNA in vitro.84 Although it is not yet
clear what effect this would have on the Dicer com-
plex, one-dimensional diffusion may allow the dsRNA
to explore a greater range of positions and orienta-
tions within the complex. Together with the flexibility
of TRBP, this could potentially facilitate RNA posi-
tioning for Dicer processing or RISC loading.
Evidence from Molecular Cell Biology
Studies
The initial evidence that TRBP and PACT bound Dicer
came from immunoprecipitation experiments using
HEK293 cells.5,6,53 In one case, epitope-tagged Dicer
was used to recover a complex containing TRBP and
Ago2 that was able to process pre-let-7 tomature let-7,
and cleave target mRNAs.52 The same studies used
RNAi to investigate the function of TRBP and PACT,
but gave somewhat contradictory results. However,
one common feature is that knocking down any of
the four components (Dicer, Ago2, TRBP, or PACT)
resulted in a decrease in levels of mature miRNA.6,53,82
There are some hints that PACT and TRBP
may act on different sets of miRNAs and/or siRNAs
(role 4). In one study, knocking down TRBP dramat-
ically reduced the effectiveness of exogenous siRNA
while having a small effect on levels of an inducible
miRNA, whereas targeting PACT had the opposite
effect.53 It is currently unclear whether knockdown of
PACT or TRBP differentially affects a certain subset
of miRNAs.
It has been reported that TRBP contains multiple
phosphorylation sites (Figure 1(c)), which modulate
its stability. When TRBP with phospho-mimic muta-
tions at these sites was transfected into human cells,
miRNA production was shown to increase relative to
controls.97 The mechanism by which this occurs is
unclear, as in vitro tests showed negligible differences
in Dicer processing between complexes containing
wild-type and phospho-mimic TRBP.55 Transfection
with phospho-mimic TRBP also caused a relative
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downregulation of the let-7 miRNA family, hinting
that TRBP may differentially affect at least some miR-
NAs (role 4).97 Although PACT also undergoes phos-
phorylation at several sites, the effects have never
been studied in the context of miRNA biogenesis.
Post-translational modification of TRBP and PACT
may indicate that their functions are context depen-
dent, and are not constitutively required.
To determine whether TRBP and PACT aid Dicer
processing (roles 1 and 2) or RISC loading (role 3),
several studies have examined how depletion of these
proteins affects silencing mediated by shRNA (which
requires processing by Dicer) or duplex siRNA (which
can in principle be incorporated directly into RISC).
The consensus is that both are affected, implying an
important role in RISC loading, while not ruling out
a supporting contribution to Dicer processing.5,53,80
Although one of these studies reports siRNA-mediated
silencing to be unaffected by depletion of TRBP or
PACT, the effectiveness of TRBP/PACT knockdown
was not measured.80 It is therefore possible that TRBP
and PACT were not effectively depleted, owing to
saturation of the RNAi machinery with luciferase
siRNA.
It is worth noting that it can be challenging
to use RNAi to knock down proteins involved in
small RNA processing, as the effectiveness of RNAi is
itself dependent on the presence and activity of these
proteins. The recent development of CRISPR/Cas
genome editing may allow future studies to avoid
this problem.98 The interpretation of experimental
data is also complicated by the possibility that these
proteins may stabilize one another. Several studies
have reported that knocking down TRBP also reduces
Dicer levels, confounding interpretation in terms of
TRBP alone,5,65,97 especially because this effect has
not been unanimously reported.6 A similar stabilizing
effect on Dicer was seen for PACT—but not for
TRBP—in a separate study.53
The majority of both TRBP and PACT is found
in the cytoplasm, particularly in the perinuclear
space, though a smaller amount is present in the
nucleus.41,80,99 Förster resonance energy transfer
experiments using fluorescently tagged TRBP and
PACT provide evidence that they interact in vivo.80
The distribution of TRBP and PACT mirrors that of
Dicer and Ago2, which are also predominantly cyto-
plasmic with a small nuclear fraction. Dicer, Ago2,
TRBP, and PACT have lower diffusion rates in the
cytoplasm than in the nucleus.99,100 This observation
has been interpreted as evidence for a large cyto-
plasmic complex that is disassembled in the nucleus.
Alternatively, it is consistent with the idea that these
proteins are anchored to a larger cytoplasmic feature,
such as P-bodies or the rough endoplasmic reticu-
lum (ER). This latter possibility is consistent with
reports of co-localization of RISC components with
ribosomes or the ER.101–103
TRBP AND PACT MEDIATE INNATE
IMMUNE SURVEILLANCE OF dsRNA
RNA viruses produce dsRNA in the course of their
lifecycle, either as genomic material or as a replica-
tion intermediate. Viral dsRNA has features that dis-
tinguish it from cellular dsRNA, which may include
its longer length, lack of the 5′ cap characteristic of
eukaryotic mRNAs, and absence of mismatches. The
innate immune system can recognize these features
through PRRs, including RIG-I, MDA5, and TLR3.
The PRRs used by mammalian cells can be
divided into ‘early’ responders, which stimulate pro-
duction of interferons and proinflammatory cytokines,
and ‘late’ responders, which directly block viral pro-
liferation through translation inhibition and RNA
degradation (Figure 1(b)). These pathways have been
reviewed in more detail elsewhere.2 TRBP and PACT
have roles in several of these pathways, and have been
implicated in the response to a number of viruses (sum-
marized in Table 1).
PACT Can Stimulate RIG-I Activation
RIG-I is an early response PRR that detects dsRNA
with a 5′ triphosphate group (5′ppp-dsRNA).104
RIG-I is ubiquitously expressed, and is one of the
main viral RNA sensors in nonimmune cells.2 The
mechanism of RIG-I activation has been character-
ized at the structural level105–107 (Figure 4(a)). In the
absence of 5′ppp-dsRNA, the tandem caspase recruit-
ment domains (CARDs) responsible for signaling are
bound to a DExD/H helicase domain, and are inac-
tive. 5′ppp-dsRNA binds to the helicase and CTDs of
RIG-I, displacing the CARDs. The CARDs then initi-
ate a signaling pathway that leads to the activation of
interferon regulatory factor 3 (IRF3), increasing tran-
scription of type 1 interferon and other antiviral genes
(Figure 1(c)). Several recent reviews have described
RIG-I function in more detail.107–109
Evidence has emerged that PACT can activate
RIG-I in response to a number of viruses7,110,111
(Table 1). Although the helicase domains of RIG-I and
Dicer are part of the same subfamily,112 it is unlikely
that PACT binds these two proteins in the same
manner: there is no evident sequence homology in the
helicase insert domain, which forms the PACT-binding
site in Dicer. This is consistent with a report that
© 2015 John Wiley & Sons, Ltd.
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TABLE 1 Evidence Linking TRBP and PACT to Viral Sensing.
Virus Details Reference
Viruses linked to TRBP and PACT
Newcastle disease virus
(NDV)
Overexpressing PACT increased type 1 interferon production
from NDV infection
113
Sendai virus RIG-I activation during infection was enhanced by PACT 7
Herpes simplex virus 1
(HSV-1)
HSV-1 protein Us11 reduces type 1 interferon production due
to PACT. Viral proteins block PACT interaction with PKR
and/or RIG-I
114,115
Ebolavirus Viral proteins VP30 and VP35 interfere with RNAi and interact
with TRBP, PACT, and/or Dicer. PACT overexpression inhibits
viral replication, while VP35 prevents PACT from activating
RIG-I
110,116
Influenza Viral proteins interact with PACT, resulting in increased viral
replication
117
MERS-CoV Viral protein 4a inhibited PACT activation of RIG-I, resulting in
reduced interferon production
111
HIV-1 TRBP blocks PKR activation by HIV transcripts. HIV was
suggested to disrupt RNAi by sequestering TRBP, but this is
disputed
118–120








virus (VSV); Sendai virus
Found no difference between PACT knockout and wild-type
cells
121
TRBP, TAR RNA-binding protein; PACT, Protein Activator of PKR; RIG-I, retinoic acid-inducible gene I; RNAi, RNA interference.
PACT binds to the CTD of RIG-I.7 There have been
no reports of TRBP interacting with RIG-I.
Many unanswered questions surround the role
of PACT in RIG-I activation. It is unclear under which
conditions PACT activates RIG-I, and the mechanism
is not known. To date, the interaction has been most
studied in the context of Sendai virus,7,110 a negative
sense single-stranded RNA (ssRNA) virus that infects
rodents. In this case, PACT can act to enhance acti-
vation of IRF3 and transcription of genes under the
control of IFN-훽. A similar effect was seen for Ebola
virus (also a negative sense ssRNA virus), and overex-
pressing PACT was able to slow viral replication.110
To counter this effect, Ebola virus encodes a protein
that is reported to disrupt the interaction between
PACT and both Dicer and RIG-I.110,116 An earlier
study found that PACT increased type 1 interferon
production in response to Newcastle disease virus,
which also has a negative sense ssRNA genome.113 It
now appears plausible that this effect was mediated by
RIG-I, although it had not been identified at the time.
One hypothesis is that PACT can extend the
range of ligands that can activate RIG-I. Overexpres-
sion of PACT did not enhance RIG-I activation by
5′-ppp dsRNA, but did enhance the response to the
dsRNA analog poly-I:C.7 However, further work will
be needed to confirm this, and to disentangle the
effects of the other RIG-I (and Dicer)-related heli-
cases, MDA5 and LGP2. MDA5 functions similarly to
RIG-I, but is activated by longer dsRNA, while LGP2
lacks the CARD signaling domains, and is thought to
inhibit RNA sensing.108 The CTDs of RIG-I, MDA5,
and LGP2 are well conserved and so it is plausible that
PACT could interact with all of them.
PACT Activates PKR, While TRBP Inhibits
It
PKR is a kinase that acts to block translation in
response to viral dsRNA, or to other cellular stresses
such as oxidative stress, accumulation of misfolded
proteins in the ER, or external signals from cytokines
and growth factors.122 It has low basal expression, but
is strongly induced by interferon,123 making it a ‘late’
responder to viruses.
PKR has two N-terminal type A dsRBDs and a
kinase domain (Figure 4(b)). The first two domains
bind dsRNA and act as a scaffold to bring PKR
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molecules close together, and increase the likelihood of
dimerization of the kinase domain.124 After dimeriza-
tion the kinase domain autophosphorylates,125 then
phosphorylates eukaryotic translation initiation fac-
tor 2훼 (eIF2훼), in turn blocking translation. The
kinase domain is present in a number of other pro-
teins that phosphorylate eIF2훼 in response to various
stresses.122 PKR function has been reviewed in more
detail elsewhere.122,124,126
TRBP and PACT can regulate PKR: TRBP has
an inhibitory effect, while PACT is a conditional
activator3,4,127 (Figure 4(b)). Domain swap and muta-
tional analyses indicate that the first two dsRBDs
of PACT and TRBP are functionally interchangeable,
and interact with the dsRBDs of PKR.9,36,128 There
is some evidence that this interaction is independent
of dsRNA, indicating that dsRBDs bind one another
directly.128 However, there is some disagreement on
this issue,129 and it has never been explicitly examined
biophysically.
The differences between PACT and TRBP stem
from their C-terminal dsRBD. In response to cellular
stresses, PACT-D3 is phosphorylated at S246 and
S287 by an unknown kinase (or kinases), leading to
activation of PKR.127 Two models have been pro-
posed to explain how PACT enables PKR activation.
First, binding of phosphorylated PACT-D3 to PKR
could cause a conformational change that promotes
activation.9 Supporting this model, PACT-D3 alone
has been reported to interact weakly with PKR.9,130
Alternatively, PACT dimers might bind two molecules
of PKR, enhancing PKR dimerization.43 This is
consistent with evidence that PACT-D3 phospho-
rylation promotes homodimerization and disfavors
heterodimerization with TRBP.42,43
In contrast, TRBP-D3 has an inhibitory effect
on PKR, which appears to be important for prevent-
ing inappropriate activation of PKR.36,131 A similar
inhibitory effect is also observed for truncated PKR
or PACT constructs containing only their first two
dsRBDs,9,132 which suggests that rather than a spe-
cific effect of TRBP-D3, anything that binds to the
dsRBDs of PKR and disrupts PKR dimerization will
cause inhibition. To our knowledge, TRBP phosphory-
lation (discussed in sectionEvidence fromBiochemical
and Biophysical Studies) has not been studied in the
context of PKR inhibition.
It is worth noting that many studies prior to
2009 used PACT constructs containing a frameshift
mutation that replaces the last 13 amino acids
(including part of a predicted helix) with 5 unre-
lated amino acids.4,9,36,41,130,132–134 This mutant
constitutively activated PKR and disrupted PACT-D3
dimerization.131
CONCLUSION
It is more than 15 years since TRBP and PACT were
found to interact with PKR, and almost 10 years
since their interaction with Dicer was uncovered. It
is therefore somewhat surprising that (with a few
exceptions116,120) there has been so little crosstalk
between these two areas of study. RNAi is a key
defense against viruses in plants and invertebrates,
and while this is no longer the case in mammals,135
it is intriguing that small RNA biogenesis and viral
sensing are still linked through PACT and TRBP. It
remains to be seen whether this is an evolutionary
accident, or whether these two proteins play a genuine
linking role that has yet to be discovered. Interestingly,
the helicase domains of Dicer and RIG-I are from the
same family, termed RIG-I-like helicases, which also
hints at an evolutionary or functional link between the
two processes.112,136 A more mundane consequence is
that results from in vivo experiments must always be
interpreted with all the roles of TRBP and PACT in
mind, even if the investigation is intended to focus on
only one.
Although much has been learnt about the func-
tion of PACT and TRBP in miRNA biogenesis, two
important questions remain unanswered: why does
miRNA biogenesis utilize dsRBD-containing proteins,
and why do vertebrates have two dsRBD-containing
proteins which appear to be partially redundant?
dsRBD-containing proteins interact with Dicer pro-
teins in plants, insects, nematodes, and mammals, sug-
gesting that there is some evolutionary pressure to con-
serve them. Results fromDrosophila demonstrate that
dsRBD-containing proteins may function at multiple
steps in small RNA biogenesis pathways, rather than
having a single role. While it is possible that this is also
true for PACT and TRBP, it currently appears more
likely that they function at the same step, potentially
on different substrates. To work out which sequence
or structural features lead to differential processing,
it will likely be necessary to measure the affinities
and processing rate of Dicer/TRBP and Dicer/PACT
on a wider range of small RNAs. A complementary
approach would be to examine on a genome-wide
scale which miRNAs are differentially affected when
TRBP or PACT are depleted from the cell.
Filling in the details of the role(s) of TRBP and
PACT in miRNA biogenesis will help to unravel the
diverse phenotypes associated with defective expres-
sion of these proteins and their homologs. These
range from infertility and growth defects in mice
and flies,94,96,137 to early onset dystonia/Parkinson’s
disease and cancer in humans.65,138 Biochemical
and biophysical experiments must be complemented
by cell and whole organism work to tease apart
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these complex conditions. Although misregulation
of particular microRNAs may play a large role, it
is plausible that additional functions for TRBP and
PACT will emerge.
Note Added in Press
We would like to alert the reader to two important
studies into TRBP and PACT that were published after
submission of this review: Kim and colleagues pro-
duced knock-outs of TRBP and/or PACT in HeLa
cells and found altered Dicer cleavage in a subset of
pre-miRNAs, but no effect on steady-state miRNA
levels or Dicer stability. They also showed hyper-
phosphorylation of TRBP by JNK during M phase.
Wilson et al. reported the 3D structure of a frag-
ment of Dicer in complex with TRBP domain 3. A
Dicer mutant deficient for TRBP and PACT bind-
ing was shown to alter strand selection and iso-miR
distribution for certain miRNAs. Please see Further
Reading.
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